$27.25
+0.38 (+1.41%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PFE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
Of the 500 shown: 352 interventional · 148 observational · 89 with posted results
Held by 19 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC, D. E. Shaw & Co., Inc., Squarepoint Ops LLC, +14 more) · FINRA short interest 4.2 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: 1 congress / 5 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B RespectivelyNCT05568719Incidence of thromboembolic eventsNon-randomized · Open-label · Other | Phase 3 | Recruiting | Diagnostic test: Testing of hepatic AAV Vector integration | Hemophilia A, Hemophilia B | 173 | 2040-02-25 | in 4,938 d | 2026-05-27 |
| A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALLNCT05748171Minimum Residual Disease (MRD) Negativity in participants achieving complete response (CR), complete response with incomplete platelet count recovery (CRp), or complete response with incomplete count recovery (CRi)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Inotuzumab ozogamicin, ALLR3 | ACUTE LYMPHOBLASTIC LEUKEMIA | 100 | 2033-05-21 | in 2,467 d | 2026-08-14 |
| A Study to Learn About the Safety of PENBRAYA During PregnancyNCT07768163observationalPercentage of Major congenital malformations | — | Recruiting | Biological: PENBRAYA | Meningococcal Disease | 50 | 2032-04-30 | in 2,081 d | 2026-08-17 |
| Tucatinib Continuation StudyNCT07768358To monitor the safety and tolerability of tucatinibOpen-label · Treatment | Phase 4 | Not yet recruiting | Drug: tucatinib | HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer, Advanced Non-Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer | 175 | 2032-03-13 | in 2,033 d | 2026-08-17 |
| Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)NCT06057402Incidence of nonserious adverse events (AEs) leading to permanent discontinuationOpen-label · Treatment | Phase 4 | Recruiting | Drug: Elranatamab | Multiple Myeloma | 80 | 2032-02-22 | in 2,013 d | 2026-07-01 |
| A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe EczemaNCT06807281Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and adverse events (AEs) that lead to study discontinuationNon-randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Abrocitinib | Atopic Dermatitis | 500 | 2032-02-22 | in 2,013 d | 2026-08-17 |
| Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric SubjectsNCT05156398Change from baseline in the mean number of migraine days per month as measured over the 12-week double-blind phase of the study in adolescents with episodic migraineRandomized · Quadruple-masked · Prevention | Phase 3 | Recruiting | Drug: Rimegepant, Placebo | Migraine | 640 | 2031-11-29 | in 1,928 d | 2026-07-29 |
| Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerNCT07392892Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigatorRandomized · Double-masked · Treatment | Phase 2/3 | Recruiting | Biological: PF-08634404, Nivolumab · Drug: Chemotherapy | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma | 840 | 2031-07-22 | in 1,798 d | 2026-08-17 |
| To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy AdultsNCT05805826Phase 1: Percentage of participants reporting local reactionsRandomized · Triple-masked · Prevention | Phase 1/2 | Active, not recruiting | Biological: C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1., C. difficile vaccine formulation 2., C. difficile vaccine formulation 3. · Other: Saline Placebo. | Clostridoides Difficile Associated Disease | 936 | 2031-06-19 | in 1,765 d | 2026-04-29 |
| A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCDNCT05431088Part ARandomized · Quadruple-masked · Treatment | Phase 2/3 | Recruiting | Drug: Osivelotor | Sickle Cell Disease | 389 | 2030-12-30 | in 1,594 d | 2026-08-18 |
| A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19NCT06923137observationalCOVID-19 outpatient encounter in adults | — | Active, not recruiting | Drug: BNT162b2 | COVID-19 SARS-CoV-2 Infection, COVID-19, COVID-19 Infection, Coronavirus Disease 2019 (COVID-19), COVID-19 (Coronavirus Disease 2019), COVID-19 Vaccination, COVID-19 Vaccines, SARS-CoV-2 Infection, COVID19, SARS-CoV-2 Infection, COVID-19 | 1 | 2030-10-31 | in 1,534 d | 2025-11-19 |
| A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT07363694Phase 2 part: Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 24Randomized · Quadruple-masked · Treatment | Phase 2/3 | Recruiting | Drug: PF-07275315 dose 1, PF-07275315-dose 2, Placebo, PF-07275315-dose 3 | Moderate to Severe Chronic Obstructive Pulmonary Disease | 1,156 | 2030-10-24 | in 1,527 d | 2026-07-27 |
| A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantNCT05623020Part 1 Dose Limiting ToxicityRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Elranatamab, Daratumumab, Lenalidomide, Dexamethasone, Bortezomib | Multiple Myeloma | 1,116 | 2030-10-18 | in 1,521 d | 2026-07-09 |
| A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative ColitisNCT07470879Number and percent of enrolled participants with clinical remission based on Modified Mayo Score (MMS) at Week 52Open-label · Treatment | Phase 2 | Recruiting | Drug: Etrasimod | Colitis, Ulcerative | 24 | 2030-09-08 | in 1,481 d | 2026-06-26 |
| Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of MigraineNCT04743141The frequency and severity of on-treatment and treatment-emergent adverse events, serious adverse events, adverse events leading to discontinuation, clinically significant lab abnormalitiesOpen-label · Treatment | Phase 3 | Recruiting | Drug: Rimegepant (PF-07899801) | Acute Treatment of Migraine | 600 | 2030-07-31 | in 1,442 d | 2026-08-14 |
| Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsNCT05145127Number of subject reporting Adverse EventsOpen-label · Treatment | Phase 3 | Recruiting | Drug: PF-06741086 | Hemophilia A, Hemophilia B | 245 | 2030-07-31 | in 1,442 d | 2026-07-01 |
| A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in KoreaNCT07497854observationalTo evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine. | — | Not yet recruiting | Drug: Rimegepant sulfate | Migraine With or Without Aura | 3,000 | 2030-07-31 | in 1,442 d | 2026-05-15 |
| A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.NCT07029828Incidence of treatment-emergent adverse events (AEs).Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Ritlecitinib higher dose, Ritlecitinib lower dose | Severe Alopecia Areata | 140 | 2030-06-26 | in 1,407 d | 2026-04-28 |
| Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung CancerNCT07226999Phase 2: Confirmed Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] based on the investigator's assessmentRandomized · Quadruple-masked · Treatment | Phase 2/3 | Recruiting | Drug: PF-08634404, Chemotherapy · Biological: Atezolizumab | Small Cell Lung Cancer (SCLC) | 550 | 2030-06-14 | in 1,395 d | 2026-08-17 |
| Litfulo Capsules Special InvestigationNCT06279221observationalProportion of participants with adverse events (AEs) | — | Active, not recruiting | Drug: LITFULO | Alopecia Areata | 487 | 2030-04-24 | in 1,344 d | 2026-03-02 |
| A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.NCT07161687observationalNumber of the participants with adverse drug reactions | — | Active, not recruiting | Drug: Marstacimab | Hemophilia A or B | 50 | 2030-04-11 | in 1,331 d | 2026-03-30 |
| Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal CancerNCT07222800Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: PF-08634404, Chemotherapy · Biological: Bevacizumab | Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases, Colorectal Neoplasms | 800 | 2030-03-29 | in 1,318 d | 2026-08-17 |
| A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.NCT07152119observationalFrequency and proportion of AEs/ADRs | — | Recruiting | Drug: Litfulo | Severe Alopecia Areata | 3,000 | 2030-03-23 | in 1,312 d | 2026-05-18 |
| Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).NCT06581848observationalIncidence of an adverse event (AE)/ adverse drug reaction (ADR) | — | Active, not recruiting | Drug: Elranatamab | Multiple Myeloma | 150 | 2030-01-31 | in 1,261 d | 2025-11-24 |
| A Study to Learn About the Study Medicine PF-08052667 in People With Bladder CancerNCT07206225Number of participants with dose limiting toxicities (DLTs) in dose escalation in Part 1 and Part 2 participants onlyOpen-label · Treatment | Phase 1 | Recruiting | Drug: PF-08052667, Sasanlimab, BCG, PF-02921367 | Non-muscle Invasive Bladder Cancer | 294 | 2030-01-29 | in 1,259 d | 2026-08-17 |
| Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to RimegepantNCT05046613observationalMajor congenital malformation (birth defect) | — | Recruiting | Other: Rimegepant, Not taking Rimegepant | Migraine | 780 | 2029-11-04 | in 1,173 d | 2026-05-05 |
| A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in KoreaNCT05733104observationalNumber of patient reporting an adverse event | — | Recruiting | — | Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection, Hospital-acquired Pneumonia | 600 | 2029-09-28 | in 1,136 d | 2025-09-03 |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsNCT06131840Number of participants with adverse events (AEs)Open-label · Treatment | Phase 1 | Recruiting | Drug: PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV) | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma | 914 | 2029-09-12 | in 1,120 d | 2026-07-22 |
| The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsNCT05203172Number of participants with adverse events leading to permanent discontinuation of study interventionNon-randomized · Open-label · Treatment | Phase 4 | Recruiting | Drug: Binimetinib only treatment, Encorafenib only Treatment, Encorafenib & Binimetinib Treatment, Treatment of Encorafenib & Binimetinib & Ribociclib, Treatment of Encorafenib & Binimetinib & Cetuximab | Solid Tumors | 46 | 2029-07-31 | in 1,077 d | 2026-04-07 |
| A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsNCT06157892Number of participants with dose limiting toxicities (DLTs) in dose escalation phaseRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: disitamab vedotin, tucatinib | Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer | 54 | 2029-07-28 | in 1,074 d | 2026-07-22 |
| Study of PF-07248144 in Advanced or Metastatic Solid TumorsNCT04606446Number of participants with dose-limiting toxicities in the Dose Escalation Arms.Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: PF-07248144, Fulvestrant, Letrozole, Palbociclib, PF-07220060, PF-07850327, ARV-471, vepdegestrant | Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer | 320 | 2029-07-13 | in 1,059 d | 2026-04-16 |
| An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced CancersNCT07426757Type, incidence and severity of participants with adverse events (AEs)Open-label · Treatment | Phase 1 | Recruiting | Drug: PF-07994525, Midazolam | Advanced Malignancies, Advanced Cancer | 120 | 2029-07-10 | in 1,056 d | 2026-08-17 |
| A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia.NCT06476665observationalOccurrence of adverse events | — | Active, not recruiting | — | Acute Lymphocytic Leukemia | 10 | 2029-06-22 | in 1,038 d | 2026-04-28 |
| A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.NCT06733337observationalIncidence of adverse drug reactions | — | Active, not recruiting | — | Prostate Cancer | 1 | 2029-06-22 | in 1,038 d | 2025-11-17 |
| An Extension Study for Treatment of Moderately to Severely Active Ulcerative ColitisNCT03950232Number and Severity of Safety MeasuresOpen-label · Treatment | Phase 3 | Active, not recruiting | Drug: Etrasimod | Ulcerative Colitis | 896 | 2029-06-19 | in 1,035 d | 2026-07-09 |
| A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative ColitisNCT05287126Proportion of Participants Achieving Clinical Remission as Assessed by Modified Mayo Score (MMS) at Week 52Open-label · Treatment | Phase 2 | Recruiting | Drug: Etrasimod | Ulcerative Colitis | 36 | 2029-06-16 | in 1,032 d | 2026-07-08 |
| A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe AsthmaNCT07772921Annualized asthma exacerbation rate over 52 weeksRandomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: tilrekimig · Other: Placebo | Asthma | 1,100 | 2029-06-12 | in 1,028 d | 2026-08-19 |
| A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.NCT07629440Percentage of participants reporting local reactions within 7 days after each doseRandomized · Quadruple-masked · Prevention | Phase 3 | Recruiting | Biological: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) | Pneumococcal Disease | 3,230 | 2029-06-05 | in 1,021 d | 2026-07-09 |
| Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial CancerNCT07578649Progression-Free Survival (PFS) using RECIST v1.1 as assessed by Blinded Independent Central Review (BICR)Randomized · Open-label · Treatment | Phase 3 | Not yet recruiting | Biological: PF-08634404, Pembrolizumab · Drug: Standard of Care Chemotherapy | Endometrial Neoplasms, Endometrial Cancer | 600 | 2029-06-01 | in 1,017 d | 2026-08-17 |
| A Study to Learn About ABRYSVO Vaccine in Older Adults to Prevent Severe Respiratory Syncytial Virus (RSV) DiseaseNCT06077968observational1. Vaccine Effectiveness (VE) calculated as 1 minus the odds ratio (OR) comparing the odds of being vaccinated with ABRYSVO for RSV-related hospitalized LRTD cases and controls, multiplied by 100%. | — | Active, not recruiting | Biological: Prior standard of care receipt of Pfizer's ABRYSVO vaccine | Respiratory Syncytial Viruses | 1 | 2029-05-01 | in 986 d | 2026-05-11 |
| A Study to Learn More About Tukysa Once it is Out in the Korean MarketNCT06873191observationalObjective Response Rate (ORR) | — | Not yet recruiting | — | HER2-positive Locally Advanced Unresectable, Metastatic Breast Cancer | 600 | 2029-05-01 | in 986 d | 2025-11-17 |
| A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsNCT07318805Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab | Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer | 260 | 2029-04-14 | in 969 d | 2026-07-22 |
| Ngenla Subcutaneous Injection Special InvestigationNCT05602766observationalThe number of patients reporting Adverse Events (AEs) | — | Active, not recruiting | Drug: NGENLA (Somatrogon) | Growth Hormone Deficiency Without Epiphyseal Closure | 1 | 2029-04-06 | in 961 d | 2025-10-02 |
| A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.NCT05295290Composite findings of myocarditisNon-randomized · Open-label · Other | Phase 4 | Active, not recruiting | Diagnostic test: Cardiac Imaging | Myocarditis | 319 | 2029-04-02 | in 957 d | 2026-05-07 |
| A Study to Learn About the Safety of TALZENNA for the Treatment of Breast CancerNCT06735742observationalIncidence of adverse drug reactions | — | Active, not recruiting | — | Breast Cancer | 3 | 2029-03-30 | in 954 d | 2025-11-17 |
| A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in JapanNCT06864585observationalNumber of Participants with adverse drug reactions (ADRs) | — | Active, not recruiting | Drug: Avibactam sodium/Ceftazidime hydrate | Infectious Diseases | 59 | 2029-03-30 | in 954 d | 2026-08-17 |
| Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced CancersNCT07227298Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: PF-08634404, Sigvotatug Vedotin, Combination Agent 1 | Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer | 162 | 2029-03-08 | in 932 d | 2026-07-22 |
| Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT07222566Overall SurvivalRandomized · Double-masked · Treatment | Phase 3 | Recruiting | Biological: PF-08634404, Pembrolizumab · Drug: Chemotherapy Regimen 1, Chemotherapy Regimen 2 | Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Metastatic Non Small Cell Lung Cancer, Lung Cancer | 1,410 | 2029-02-27 | in 923 d | 2026-08-17 |
| A Study on Paxlovid Once in the Market, to Observe Its Safety and Effectiveness in Patients Who Have a High Chance of Getting Severe COVID-19NCT05890612observationalProportion of patients with an adverse event (AE) | — | Recruiting | — | COVID-19 | 3,000 | 2029-02-17 | in 913 d | 2026-08-12 |
| An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative ColitisNCT07459686observationalThe incidence of serious infections (adverse events and adverse drug reactions) and safety specifications (adverse drug reactions) | — | Recruiting | Drug: Velsipity | Ulcerative Colitis (UC) | 553 | 2029-01-29 | in 894 d | 2026-05-18 |
| Randomized Study in Children and Adolescents With Migraine: Acute TreatmentNCT04649242To evaluate the efficacy of rimegepant compared with placebo in the acute treatment of migraine in adolescent population (≥ 12 to <18 years of age) as measured by pain freedom using the number of patients reporting no pain.Randomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: Rimegepant/BHV3000, Matching placebo | Pediatric Migraine | 2,100 | 2029-01-09 | in 874 d | 2026-08-14 |
| Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseNCT06760637Progression Free Survival (PFS) by BICRRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib | Breast Cancer | 1,035 | 2029-01-02 | in 867 d | 2026-05-19 |
| A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy InfantsNCT07573462Percentage of participants reporting local reactions within 7 days after each doseRandomized · Quadruple-masked · Prevention | Phase 3 | Recruiting | Biological: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) | Pneumococcal Disease | 2,400 | 2028-12-30 | in 864 d | 2026-08-10 |
| Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical CancerNCT06952660Type, incidence and severity of ocular adverse events (AEs)Open-label · Other | Phase 4 | Recruiting | Drug: TIVDAK | Cervical Cancer | 100 | 2028-12-13 | in 847 d | 2026-08-17 |
| A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and OlderNCT07282665The percentage of participants reporting local reactionsRandomized · Quadruple-masked · Prevention | Phase 3 | Recruiting | Biological: C.difficile vaccine · Other: Saline Placebo | Clostridoides Difficile Associated Disease | 32,500 | 2028-12-11 | in 845 d | 2026-08-14 |
| Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World ContextNCT06487078Progression-Free Survival (PFS)Open-label · Treatment | Not applicable | Recruiting | Drug: Lorlatinib | ALK+ Non-Small-Cell Lung Carcinoma | 90 | 2028-11-30 | in 834 d | 2026-05-06 |
| A Study to Evaluate 20vPnC in Healthy Chinese InfantsNCT07754539Percentage of participants reporting prespecified local reactionsRandomized · Triple-masked · Prevention | Phase 3 | Recruiting | Biological: 20vPnC, 13vPnC | Pneumococcal Diseases | 1,250 | 2028-11-30 | in 834 d | 2026-08-10 |
| BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their BabiesNCT07160244The proportion of maternal participants reporting prespecified local reactions within 7 days following study interventionRandomized · Quadruple-masked · Prevention | Phase 3 | Recruiting | Biological: Multivalent Group B streptococcus vaccine, Placebo, Infanrix hexa, Prevenar 20, Pediarix, Prevnar 20, Infanrix | Healthy | 6,000 | 2028-11-06 | in 810 d | 2026-07-09 |
| Korea Post Marketing Surveillance (PMS) Study of Talzenna®NCT04982848observationalIncidence of adverse events categorized according to physical organ and disease/symptom | — | Not yet recruiting | Drug: Talzenna | Breast Neoplasms | 600 | 2028-11-01 | in 805 d | 2025-11-18 |
| A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.NCT05387980observationalNumber of Participants with adverse drug reactions | — | Active, not recruiting | Drug: CIBINQO | Atopic Dermatitis | 1,128 | 2028-11-01 | in 805 d | 2026-03-19 |
| This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.NCT07028853Radiographic Progression Free Survival (rPFS)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Mevrometostat, Placebo, Enzalutamide | Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate | 1,000 | 2028-09-12 | in 755 d | 2026-08-14 |
| A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic MigraineNCT07729462Change From Observation Phase in Monthly Migraine Days (MMDs) Over the Entire Double-Blind Treatment PhaseRandomized · Quadruple-masked · Prevention | Phase 3 | Not yet recruiting | Drug: Rimegepant, Placebo | Preventive Treatment of Migraine | 400 | 2028-09-12 | in 755 d | 2026-07-27 |
| A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BNCT05611801Annualized bleeding rate (ABR) of treated bleeding eventsOpen-label · Treatment | Phase 3 | Recruiting | Drug: marstacimab | Hemophilia A, Hemophilia B | 100 | 2028-09-10 | in 753 d | 2026-08-10 |
| This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.NCT06758401Overall SurvivalRandomized · Single-masked · Treatment | Phase 3 | Recruiting | Drug: Sigvotatug Vedotin, Pembrolizumab | Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC) | 714 | 2028-09-05 | in 748 d | 2026-07-22 |
| A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent MigraineNCT06616194Number of migraine days per monthRandomized · Quadruple-masked · Prevention | Phase 3 | Active, not recruiting | Drug: Rimegepant, Placebo | Migraine | 200 | 2028-08-19 | in 731 d | 2026-07-30 |
| Safety and Efficacy Study of PF-06835375 in Primary Immune ThrombocytopeniaNCT05070845Proportion of participants with change from baseline of platelet countsOpen-label · Treatment | Phase 2 | Recruiting | Biological: PF-06835375 | Primary Immune Thrombocytopenia | 91 | 2028-08-02 | in 714 d | 2026-05-12 |
| Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLCNCT07489066Number of Participants With Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Biological: PF-08634404 · Drug: Chemotherapy Regimen 1, Chemotherapy Regimen 2 | Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous | 120 | 2028-07-29 | in 710 d | 2026-08-17 |
| A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489NCT07073820Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Open-label · Treatment | Phase 2 | Recruiting | Drug: PF-07868489 | Pulmonary Hypertension | 36 | 2028-07-18 | in 699 d | 2026-05-19 |
| Phase 1 Study of PF-08046033 in Advanced Solid TumorsNCT07519655Type, incidence and severity of participants with adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: PF-08046033 | Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma | 250 | 2028-07-14 | in 695 d | 2026-08-17 |
| A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499Incidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluationOpen-label · Treatment | Phase 1 | Recruiting | Drug: PF-08046876 | Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer | 310 | 2028-07-08 | in 689 d | 2026-07-22 |
| A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).NCT06297161observationalIncidence of AEs | — | Recruiting | Drug: Bosulif | Chronic Leukemia Myelogenous | 600 | 2028-06-01 | in 652 d | 2026-04-14 |
| A Study to Learn About a Vaccine Against E Coli in Healthy AdultsNCT07122986Percentage of participants reporting prespecified local events within 7 days following each vaccinationRandomized · Double-masked · Basic science | Phase 1 | Recruiting | Drug: E coli vaccine 1 Dose A, E coli vaccine 1 Dose B, E coli vaccine 2, E coli vaccine 3, E coli Vaccine 4 Dose A, E coli Vaccine 4 Dose B, E coli Vaccine 4 Dose C, E coli Vaccine 5 Dose A, E coli Vaccine 5 Dose B, Placebo | Healthy Participants | 310 | 2028-05-26 | in 646 d | 2026-04-30 |
| A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With MigraineNCT07609914Incidence of Treatment-Emergent Adverse Events (TEAEs), serious TEAEs, and TEAEs leading to study intervention discontinuation on treatment by average monthly redosing frequency over the entire OLT phase (<3, ≥3 to <6, ≥6 re-doses per month) and overallNon-randomized · Open-label · Treatment | Phase 4 | Recruiting | Drug: Rimegepant | Acute Treatment of Migraine | 400 | 2028-05-15 | in 635 d | 2026-07-29 |
| A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or ObesityNCT07595549Percent change from baseline in body weightRandomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: PF-08653944 · Other: Placebo | Obesity, Overweight and/or Obesity, Overweight | 954 | 2028-05-04 | in 624 d | 2026-08-17 |
| ATTR-CM: A Multi-country, Non-interventional Disease RegistryNCT06651073observationalDemographic data | — | Active, not recruiting | Other: Observational | Transthyretin Amyloid Cardiopathy | 350 | 2028-04-28 | in 618 d | 2026-02-19 |
| A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia AreataNCT07733765Difference in the proportion of Severity of Alopecia Tool (SALT) 0 responders at Week 24 between ritlecitinib 50 mg QD versus placeboRandomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: Ritlecitinib 100 mg, Ritlecitinib 50 mg · Other: Placebo | Alopecia Areata | 336 | 2028-04-27 | in 617 d | 2026-07-29 |
| A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.NCT05355701Number of participants with dose limiting toxicities (DLTs) (Part 1 and Part 2)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: PF-07799933, binimetinib, midazolam, fluorouracil, leucovorin, oxaliplatin · Biological: cetuximab | Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1) | 267 | 2028-04-23 | in 613 d | 2026-07-31 |
| A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaNCT03460977Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Mervometostat (PF-06821497), Enzalutamide, Itraconazole | Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL) | 453 | 2028-04-20 | in 610 d | 2026-07-29 |
| Study of Pregnancy Outcomes in Women Exposed to Rimegepant During PregnancyNCT05198245observationalMajor congenital malformations, spontaneous abortions, fetal deaths/stillbirths, small for gestational age births | — | Active, not recruiting | Drug: Rimegepant, Various · Other: No intervention | Migraine | 1 | 2028-04-17 | in 607 d | 2026-01-08 |
| Characterization And Clinical Outcomes of AA Patients Treated With RitlecitinibNCT06531109observationalPercentage change from baseline in Severity of Alopecia Tool (SALT) score at week 24 | — | Recruiting | Drug: Ritlecitinib | Alopecia Areata | 450 | 2028-04-15 | in 605 d | 2026-07-23 |
| First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.NCT04767594observationalProgression-free survival (PFS) | — | Active, not recruiting | Drug: Palbociclib + endocrine therapy | Breast Neoplasms | 1,407 | 2028-04-03 | in 593 d | 2026-04-13 |
| Crizotinib Continuation Clinical StudyNCT05160922Number of participants with adverse events leading to permanent discontinuation of study interventionOpen-label · Treatment | Phase 4 | Active, not recruiting | Drug: crizotinib | NSCLC, ALCL, IMT | 27 | 2028-03-21 | in 580 d | 2026-03-30 |
| A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia AreataNCT06873945Part 1: Percentage of participants with absolute Severity of Alopecia Tool (SALT) score less than or equal to 20Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg, Placebo - 50 mg | Alopecia Areata | 1,330 | 2028-03-19 | in 578 d | 2026-08-13 |
| Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung CancerNCT07476287Confirmed Objective Response Rate (ORR) as assessed by investigator based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)Open-label · Treatment | Phase 2 | Recruiting | Drug: PF-08634404, Chemotherapy | Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Small Cell Lung, Small Cell Cancer Of The Lung | 40 | 2028-03-19 | in 578 d | 2026-08-17 |
| A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280Overall SurvivalRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: PF-08046054, Docetaxel monotherapy | Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma | 680 | 2028-03-10 | in 569 d | 2026-08-17 |
| A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe EczemaNCT07765888Difference in the proportion of Eczema and Severity Index (EASI)75 responders between tilrekimig versus placeboRandomized · Quadruple-masked · Treatment | Phase 3 | Not yet recruiting | Drug: Tilrekimig · Other: Placebo | Atopic Dermatitis | 375 | 2028-02-29 | in 559 d | 2026-08-14 |
| A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single DoseNCT06866405Percentage of pregnant participants reporting local reactionsRandomized · Quadruple-masked · Prevention | Phase 3 | Recruiting | Biological: RSVpreF, Placebo | RSV Infection | 550 | 2028-02-24 | in 554 d | 2026-08-14 |
| A Study to Learn About Study Medicine Called PF-08049820 in People With EczemaNCT07216027Percent change from baseline in Eczema Area and Severity Index (EASI) total score at Week 12Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: PF-08049820, Placebo | Atopic Dermatitis, Eczema, Atopic | 165 | 2028-02-02 | in 532 d | 2026-08-17 |
| A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Weight LossNCT07663630Percent change from baseline in Lumbar Skeletal Muscle IndexRandomized · Quadruple-masked · Supportive care | Phase 1 | Not yet recruiting | Drug: ponsegromab, placebo | Non-small Cell Lung Cancer (NSCLC), Cachexia | 80 | 2028-02-02 | in 532 d | 2026-06-23 |
| A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised AdultsNCT07768345Percentage of participants reporting local reactionsNon-randomized · Open-label · Prevention | Phase 3 | Not yet recruiting | Biological: RSVpreF Vaccine | Respiratory Syncytial Virus (RSV) | 440 | 2028-02-02 | in 532 d | 2026-08-17 |
| Post Marketing Surveillance(PMS) Study of Lorviqua in KoreaNCT05599412observationalIncidence of the adverse events from baseline | — | Recruiting | Drug: Lorviqua | Metastatic ALK+ Non Small Cell Lung Cancer | 600 | 2028-01-31 | in 530 d | 2026-03-27 |
| A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in TaiwanNCT07391761observationalrwTTR (real-world time to response) | — | Active, not recruiting | Drug: Non intervention | Refractory Multiple Myeloma (RRMM) | 1 | 2028-01-31 | in 530 d | 2026-07-01 |
| A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy AdultsNCT07226882Geometric Mean Concentration (GMC) of Anti-Outer Surface Protein A (OspA) Immunoglobulin G (IgG)Randomized · Triple-masked · Prevention | Phase 3 | Active, not recruiting | Biological: VLA15, Placebo | Lyme Borreliosis | 207 | 2028-01-27 | in 526 d | 2026-05-06 |
| A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and FatigueNCT06989437Percent change from baseline in body weight for ponsegromab compared to placeboRandomized · Quadruple-masked · Treatment | Phase 2/3 | Recruiting | Drug: ponsegromab, placebo | Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma | 982 | 2028-01-17 | in 516 d | 2026-07-09 |
| A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in IndiaNCT07685769Incidence of Treatment-emergent adverse events (TEAEs)Open-label · Treatment | Phase 4 | Not yet recruiting | Drug: Rimegepant 75 mg ODT | Acute Treatment of Migraine | 60 | 2028-01-11 | in 510 d | 2026-07-06 |
| A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsNCT05208762Number of participants with adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: PF-08046054, pembrolizumab | Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms, Gastric Cancer, Endometrial Cancer, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma | 714 | 2028-01-05 | in 504 d | 2026-07-22 |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerNCT05253651Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: tucatinib, trastuzumab, bevacizumab, cetuximab, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Colorectal Neoplasms | 400 | 2027-12-31 | in 499 d | 2026-07-22 |
| A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.NCT05689151observationalProportion of patients with an Investigator's Global Assessment (IGA) score of clear (0) or almost clear (1) (on a 5- point scale) and a reduction from baseline of ≥2 points | — | Recruiting | Drug: Abrocitinib | Atopic Dermatitis, Eczema | 183 | 2027-12-31 | in 499 d | 2026-07-07 |
| A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their OffspringNCT05721937observationalPercent of live birth children with major congenital malformations | — | Recruiting | Drug: Abrocitinib | Atopic Dermatitis | 400 | 2027-12-31 | in 499 d | 2025-12-09 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy AdultsNCT06994897Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE)Randomized · Double-masked · Basic science | Phase 1 | Recruiting | Drug: PF-07985631, Placebo | Healthy | 92 | 2027-12-08 | in 476 d | 2026-03-20 |
| Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerNCT07421700Confirmed Objective Response Rate (ORR) by investigatorNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: PF-08634404, Enfortumab Vedotin | Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma | 132 | 2027-12-06 | in 474 d | 2026-08-17 |
| Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and AdolescentsNCT07660198Percentage of Participants With Local Reactions Within 7 Days After VaccinationRandomized · Triple-masked · Prevention | Phase 3 | Recruiting | Biological: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) | Pneumococcal Disease | 1,200 | 2027-12-02 | in 470 d | 2026-07-09 |
| A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory MyopathiesNCT06698796Treatment-Emergent Adverse Events (AEs), Serious AEs, AEs of Special Interest, and AEs leading to treatment discontinuationOpen-label · Treatment | Phase 3 | Recruiting | Drug: Dazukibart | Dermatomyositis, Polymyositis | 211 | 2027-11-25 | in 463 d | 2026-05-15 |
| A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic DermatitisNCT05391061observationalNumber of participants with Adverse Events (AE's) according to frequency | — | Recruiting | Drug: Abrocitinib | Dermatitis, Atopic | 1,100 | 2027-11-22 | in 460 d | 2025-12-09 |
| A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)NCT06991257Number of Participants with Clinical EventsRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: Placebo, Low Dose PF-07328948, Medium Dose PF-07328948, High Dose PF-07328948 | Heart Failure | 620 | 2027-11-16 | in 454 d | 2026-05-27 |
| Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerNCT07227415Confirmed objective response rate (ORR) using RECIST v1.1 as assessed by investigatorRandomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: PF-08634404, Ipilimumab, Axitinib | Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell Metastasis, Advanced or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Advanced, Metastatic Renal Cell Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic/Advanced Renal Cell Carcinoma | 224 | 2027-11-02 | in 440 d | 2026-07-06 |
| SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDERNCT06546800observationalPercentage of individuals aged 60 years or older reporting Adverse Reactions for 28 days after vaccination. | — | Active, not recruiting | Biological: RSVpreF vaccine | Respiratory Syncytial Virus Infection | 1,100 | 2027-10-28 | in 435 d | 2026-02-04 |
| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast CancerNCT06966453Objective response (OR) by investigator assessmentNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Disitamab vedotin | Breast Cancer, Breast Neoplasms | 100 | 2027-10-25 | in 432 d | 2026-04-21 |
| A Study to Learn About How a New Pneumococcal Vaccine Works in AdultsNCT07086677Percentage of participants reporting prespecified local reactions after each dose.Randomized · Double-masked · Prevention | Phase 1 | Active, not recruiting | Biological: PG4 vaccine in Buffer 1 with low dose PA-001, PG4 in Buffer 1 with low dose PA-002, PG4 in Buffer 1 with high dose PA-001, PG4 vaccine in Buffer 1 with high dose PA-002, PG4 vaccine in Buffer 2, 20-valent pneumococcal conjugate vaccine, Saline injection | Streptococcus Pneumoniae | 380 | 2027-10-21 | in 428 d | 2026-06-22 |
| Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.NCT07227012Number of Participants With Adverse EventsRandomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: PF-08634404, Ipilimumab | Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Liver Neoplasms, Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | 138 | 2027-10-18 | in 425 d | 2026-08-17 |
| A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)NCT07400653Percent Change from baseline in body weightRandomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: PF-08653944 · Other: Placebo | Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2, Type 2 Diabetes | 1,044 | 2027-10-12 | in 419 d | 2026-07-27 |
| A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe DiseaseNCT06679140Proportion of participants with COVID-19 related emergency department visits, all cause hospitalization and all cause mortalityRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: ibuzatrelvir, placebo | COVID-19 SARS-CoV-2 Infection | 2,330 | 2027-10-03 | in 410 d | 2026-08-14 |
| An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative ColitisNCT06398626observationalProportion of patients with symptomatic remission | — | Recruiting | Drug: Etrasimod | Colitis, Ulcerative | 300 | 2027-10-01 | in 408 d | 2026-07-09 |
| Evaluating ABRYSVO Maternal Vaccine Effectiveness Among InfantsNCT07249320observationalPolymerase chain reaction (PCR)-confirmed RSV LRTD occurring ≤180 days after birth (first episode). | — | Active, not recruiting | Biological: ABRYSVO | Respiratory Syncytial Virus (RSV) | 1 | 2027-09-30 | in 407 d | 2026-06-10 |
| A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely ImmunocompromisedNCT07013474The difference in the proportion of patients meeting the primary composite endpoint, between ibuzatrelvir and remdesivir vs remdesivir groups in symptomatic adult participants with COVID-19 who are severely immunocompromisedRandomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: ibuzatrelvir, remdesivir, placebo for ibuzatrelvir, placebo for remdesivir | COVID-19 Infection | 300 | 2027-09-27 | in 404 d | 2026-08-14 |
| Efficacy and Safety of MET097 Once-Weekly in People With Overweight or ObesityNCT07311850Percent change from baseline in body weightRandomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: MET097, Placebo | Obesity and Overweight | 3,578 | 2027-09-21 | in 398 d | 2026-08-17 |
| A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid LeukemiaNCT05189639observationalNumber of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) | — | Recruiting | — | Acute Myeloid Leukemia | 165 | 2027-08-30 | in 376 d | 2026-07-24 |
| A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver DiseaseNCT07677358Maximum Observed Plasma Concentration (Cmax) for atirmociclib in participants with normal hepatic functionOpen-label · Other | Phase 1 | Not yet recruiting | Drug: Atirmociclib | Hepatic Impairment, Healthy, Hepatic Insufficiency, Healthy Adults | 28 | 2027-08-14 | in 360 d | 2026-06-30 |
| A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of MigraineNCT06995729Maximum Observed Plasma Concentration (Cmax)Open-label · Treatment | Phase 1 | Recruiting | Drug: Zavegepant | Acute Treatment of Migraine | 16 | 2027-08-12 | in 358 d | 2026-03-18 |
| Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After TransplantNCT05317416Progression Free SurvivalRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Elranatamab, Lenalidomide, Lenalidomide, Elranatamab | Multiple Myeloma | 854 | 2027-08-04 | in 350 d | 2026-04-16 |
| A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)NCT07575932Percent change from baseline in body weightRandomized · Double-masked · Treatment | Phase 2 | Recruiting | Drug: PF-08653945, PF-08653944, Placebo | Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity, Overnutrition, Nutrition Disorders, Nutritional and Metabolic Diseases, Body Weight | 872 | 2027-08-04 | in 350 d | 2026-08-17 |
| A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsNCT05538130Phase 1a monotherapy and Phase 1b combination dose escalation: Number of participants with dose limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: PF-07799544, PF-07799933 | Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Advanced or Metastatic Solid Tumors, HGG, LGG, Low Grade Glioma, High Grade Glioma, Differentiated Thyroid Cancer, NSCLC (Non-small Cell Lung Cancer) | 124 | 2027-08-02 | in 348 d | 2026-08-14 |
| Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western PennsylvaniaNCT06813872observationalRSV-positive ARI hospitalization confirmed by ³1 ARI symptom, laboratory testing, and hospitalization occurring 0 to ≤ 90 days of life during RSV season based on local epidemiology. | — | Active, not recruiting | Biological: ABRYSVO Vaccination | Respiratory Syncytial Viruses | 1 | 2027-07-31 | in 346 d | 2026-02-03 |
| A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2NCT06072183US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and Total body Vitiligo Area Scoring Index 50 (T-VASI50) at Week 52Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Ritlecitinib, Ritlecitinib, Placebo | Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo | 1,571 | 2027-07-30 | in 345 d | 2026-06-24 |
| A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]NCT05895786Moderate change in Total Improvement Score (TIS)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: PF-06823859, Placebo | Myositis | 318 | 2027-07-28 | in 343 d | 2026-06-01 |
| A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.NCT07062965Progression Free Survival (PFS) as determined by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: PF-07248144, Fulvestrant, Everolimus, Exemestane | Breast Cancer | 400 | 2027-07-22 | in 337 d | 2026-05-06 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 Are Tolerated and Act in the Body of Healthy AdultsNCT07235163Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Randomized · Double-masked · Basic science | Phase 1 | Not yet recruiting | Drug: PF-08065010, Placebo | Healthy | 100 | 2027-07-16 | in 331 d | 2026-03-19 |
| A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver FunctionNCT07519135Pharmacokinetics (PK): Maximum observed plasma concentration (Cmax) of PF-08653944Open-label · Basic science | Phase 1 | Recruiting | Drug: PF-08653944 | Healthy | 26 | 2027-07-09 | in 324 d | 2026-04-23 |
| A Safety Study of SEA-CD70 in Patients With Myeloid MalignanciesNCT04227847Number of participants with adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: SEA-CD70, azacitidine, Venetoclax | Myelodysplastic Syndrome, Acute Myeloid Leukemia | 178 | 2027-07-04 | in 319 d | 2026-07-22 |
| A Study to Learn About mRNA Vaccines Against Influenza in AdultsNCT07431853Percentage of participants reporting prespecified local reactions following vaccinationRandomized · Quadruple-masked · Prevention | Phase 2 | Recruiting | Biological: Vaccine Candidate #1, Vaccine Candidate #2, Vaccine Candidate #3, Vaccine Candidate #4, Vaccine Candidate #5, Vaccine Candidate #6, TIV1 or TIV2 | Healthy Adults | 770 | 2027-06-22 | in 307 d | 2026-05-06 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate AsthmaNCT07660731Number of Participants with Treatment Emergent Adverse Events (TEAEs)Randomized · Double-masked · Basic science | Phase 1 | Recruiting | Drug: PF-08103402, Placebo, Midazolam | Healthy Volunteer Study, Healthy Adults, Healthy Participants, Asthma | 139 | 2027-06-18 | in 303 d | 2026-06-29 |
| A Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632Number of participants with adverse events (AEs)Open-label · Treatment | Phase 1 | Recruiting | Drug: sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms | 1,006 | 2027-06-16 | in 301 d | 2026-07-06 |
| A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world SettingNCT05452941observationalEffectiveness of 20vPnC against all (invasive + non-invasive) RAD+CAP due to the 7 additional serotypes in 20vPnC beyond 13vPnC plus 15C | — | Recruiting | Diagnostic test: Diagnostic test on urine samples | Pneumonia | 12,500 | 2027-06-04 | in 289 d | 2026-05-11 |
| FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and PatientsNCT06564389Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and serious adverse events (SAEs) Following single ascending doses (SAD)Randomized · Triple-masked · Treatment | Phase 1 | Recruiting | Drug: PF-07832837 · Other: Placebo | Healthy Participants, Atopic Dermatitis | 119 | 2027-06-02 | in 287 d | 2026-07-22 |
| A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and InfantNCT07023081Percentage of participants reporting prespecified local reactions within 7 days following each study interventionRandomized · Open-label · Prevention | Phase 1 | Active, not recruiting | Biological: 20vPnC, 13vPnC | Pneumococcal Disease | 200 | 2027-05-14 | in 268 d | 2026-03-12 |
| A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.NCT06703606Incidence of marstacimab-related adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: MARSTACIMAB | Severe Hemophilia A | 15 | 2027-05-05 | in 259 d | 2026-06-03 |
| A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe EczemaNCT06807268Response based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at Week 12Randomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: Abrocitinib · Other: Placebo | Eczema | 150 | 2027-05-02 | in 256 d | 2026-08-17 |
| A Study to Learn About How a New Pneumococcal Vaccine Works in InfantsNCT06524414Percentage of participants reporting local reactions within 7 days after each doseRandomized · Quadruple-masked · Prevention | Phase 2 | Active, not recruiting | Biological: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15) | Pneumococcal Disease | 605 | 2027-05-01 | in 255 d | 2026-07-09 |
| STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)NCT07122661observationalEstimate vaccine effectiveness of ABRYSVO during pregnancy against RSV-positive lower respiratory tract disease hospitalisation among infants. | — | Active, not recruiting | Biological: ABRYSVO | Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus, Lower Respiratory Tract Disease, Respiratory Tract Diseases, Acute Respiratory Illness (ARI) | 1 | 2027-04-30 | in 254 d | 2025-11-19 |
| A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)NCT06462235Maximum Predicted Plasma Concentration (Cmax) of ATM and AVINon-randomized · Open-label · Basic science | Phase 2 | Recruiting | Drug: Part A: ATM-AVI Single Dose, Cohorts 1-4, Part B: Multiple-dose ATM-AVI, Cohorts 1-4 | Gram-negative Bacterial Infection | 48 | 2027-04-25 | in 249 d | 2026-06-11 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have ObesityNCT07731139Incidence of treatment emergent adverse events (TEAE)Randomized · Double-masked · Basic science | Phase 1 | Not yet recruiting | Drug: PF-08642534, Placebo | Obesity | 120 | 2027-04-21 | in 245 d | 2026-07-28 |
| A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)NCT06215118Part 1: Number of participants with dose limiting toxicity (DLT)Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Elranatamab, Iberdomide | Multiple Myeloma | 87 | 2027-04-10 | in 234 d | 2026-06-10 |
| Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative InfectionsNCT05639647Maximum Predicted Plasma Concentration (Cmax) of ATM and AVIRandomized · Single-masked · Treatment | Phase 2 | Recruiting | Drug: ATM-AVI, BAT | Gram-negative Bacterial Infections | 48 | 2027-03-31 | in 224 d | 2026-07-01 |
| A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental VitiligoNCT06163326Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to discontinuationRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Ritlecitinib, Ritlecitinib 100 mg, Placebo | Vitiligo | 394 | 2027-03-31 | in 224 d | 2026-04-29 |
| Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative ColitisNCT04624230Remission by central read Mayo score following 44 weeks in the maintenance phase.Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: tofacitinib | Ulcerative Colitis | 118 | 2027-03-17 | in 210 d | 2026-08-03 |
| A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney FunctionNCT07315360Fraction of Unbound Drug in Plasma (Fu) of PF-07328948Non-randomized · Open-label · Basic science | Phase 1 | Recruiting | Drug: PF-07328948 | Renal Impairment, Healthy | 28 | 2027-03-13 | in 206 d | 2026-05-12 |
| A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaNCT06977581Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: PF-07275315 · Other: Placebo | Asthma | 252 | 2027-03-08 | in 201 d | 2026-05-04 |
| A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.NCT07228390Difference in proportion of responders based on Hidradenitis Suppurativa Clinical Response achieving at least 50% reduction from baseline (Hidradenitis Suppurativa Clinical Response HiSCR50) in patients with HS treated with ritlecitinib versus placebo.Randomized · Triple-masked · Treatment | Phase 2 | Recruiting | Drug: Ritlecitinib, Placebo | Hidradenitis Suppurativa | 240 | 2027-03-05 | in 198 d | 2026-07-09 |
| A Study to Learn More About Prevenar 20 Once it is Out in the Korean MarketNCT06760208observationalFrequency of solicited systemic reactions | — | Recruiting | Biological: Pneumococcal 20-valent conjugate vaccine | Pneumococcal Immunization, Safety | 660 | 2027-03-01 | in 194 d | 2026-03-12 |
| Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.NCT06479954observationalIncidence of CRS events in adverse drug reaction | — | Active, not recruiting | — | Relapsed and Refractory Multiple Myeloma (RRMM) | 1 | 2027-02-25 | in 190 d | 2025-10-02 |
| A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver FunctionNCT07269301Fraction of Unbound Drug in Plasma (Fu) of PF-07328948Non-randomized · Open-label · Basic science | Phase 1 | Recruiting | Drug: PF-07328948 | Hepatic Impairment, Healthy | 26 | 2027-02-23 | in 188 d | 2026-07-23 |
| Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.NCT06899204observationalPercentage of patients achieving EASI-75 improvement from baseline at Week 16 after index date | — | Recruiting | Drug: Abrocitinib | Atopic Dermatitis, Atopic Dermatitis, Unspecified, Dermatitis, Atopic | 150 | 2027-02-15 | in 180 d | 2026-08-17 |
| A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy AdultsNCT06507904Part 1: Mouth Feel EffectRandomized · Open-label · Supportive care | Phase 1 | Not yet recruiting | Drug: Osivelotor · Other: Famotidine | Healthy | 52 | 2027-02-12 | in 177 d | 2026-03-27 |
| A Study to Look at the Health Outcomes of Patients With COVID-19 and InfluenzaNCT05160636observationalChange in Health Related Quality of Life (HRQoL) using EQ-5D-5L | — | Active, not recruiting | Biological: COVID-19 Vaccine | COVID-19, Coronavirus Disease 2019, Influenza | 999 | 2027-01-31 | in 165 d | 2026-03-31 |
| Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2NCT05911295Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: disitamab vedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin | Urothelial Carcinoma | 412 | 2027-01-29 | in 163 d | 2026-07-22 |
| A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or ObesityNCT07508241Acetaminophen Pharmacokinetic (PK) Parameters: Maximum observed plasma concentration (Cmax)Open-label · Basic science | Phase 1 | Active, not recruiting | Drug: PF-08653944, Acetaminophen | Obesity, Overweight and/or Obesity, Overweight, Drug Interaction | 22 | 2027-01-27 | in 161 d | 2026-07-09 |
| A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreFNCT07653100Proportion of participants reporting local reactions within 7 days following investigational product administrationRandomized · Double-masked · Prevention | Phase 3 | Recruiting | Biological: RSVpreF, Placebo | Respiratory Syncytial Virus (RSV) | 540 | 2027-01-25 | in 159 d | 2026-08-14 |
| Korea Comirnaty Post-marketing SurveillanceNCT05032976observationalNumber of subjects with Solicited adverse events | — | Active, not recruiting | Biological: Tozinameran 12 Years of age and older, Tozinameran 5 to 11 Years of age, Tozinameran 6 months to 4 years of age, Riltozinameran 12 Years of age and older, Famtozinameran 12 Years of age and older, Famtozinameran 5 to 11 Years of age, Raxtozinameran 12 years of age and older, Raxtozinameran 6 months to 4 years of age | COVID-19, Vaccines, Adverse Effects, SARS-CoV-2, Safety | 12,000 | 2027-01-24 | in 158 d | 2026-04-23 |
| ATGAM General InvestigationNCT06039020observationalNumber of participants with adverse drug reactions (ADRs) | — | Active, not recruiting | Drug: Anti-human thymocyte immunoglobulin, equine | Aplastic Anemia | 1 | 2027-01-22 | in 156 d | 2025-11-18 |
| Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.NCT05035212Efficacy Study: Number of first episode of RSV-associated lower respiratory tract illness (LRTI-RSV) in the first RSV seasonRandomized · Triple-masked · Prevention | Phase 3 | Active, not recruiting | Biological: RSVpreF, Placebo | Lower Respiratory Tract Illness | 38,861 | 2027-01-18 | in 152 d | 2026-01-28 |
| A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or ObesityNCT07725809Pharmacokinetics (PK): Area Under the Curve (AUC) of PF-08653945Randomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: PF-08653945 | Overweight, Obesity, Healthy | 57 | 2027-01-13 | in 147 d | 2026-07-24 |
| PF-07104091 as a Single Agent and in Combination TherapyNCT04553133Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycleNon-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: PF-07104091 monotherapy dose escalation, PF-07104091 + palbociclib + fulvestrant, PF-07104091 + palbociclib + letrozole, PF-07104091 monotherapy dose expansion (ovarian), PF-07104091 monotherapy dose expansion (SCLC), PF-07104091 + Fulvestrant (post CDK4/6), PF-0704091 + Fulvestrant (post CDK4/6) | Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer | 157 | 2026-12-31 | in 134 d | 2026-05-06 |
| Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid CardiomyopathyNCT04801329observationalThe incidence of Adverse Events (AEs) | — | Active, not recruiting | Drug: Vyndamax (tafamidis 61mg) | ATTR-CM (Transthyretin Amyloid Cardiomyopathy) | 110 | 2026-12-31 | in 134 d | 2026-03-30 |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingNCT05059522Number of participants with adverse events leading to permanent discontinuation of study interventionNon-randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, PF04518600 | Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors | 77 | 2026-12-31 | in 134 d | 2026-06-22 |
| Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesNCT05226871Number/Percentage of Participants with Treatment-Emergent Adverse Events (AEs) Leading to Permanent Discontinuation of Study Treatment and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Palbociclib, Cetuximab, Fulvestrant, Letrozole | Breast Cancer, Head and Neck Cancer | 35 | 2026-12-31 | in 134 d | 2025-11-25 |
| Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)NCT05382364Percentage of participants with ≥1 adverse event (AE)Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Tucatinib | Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer | 25 | 2026-12-31 | in 134 d | 2026-03-12 |
| TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)NCT06125522Phase 1b: Number of Participants With Dose Limiting ToxicitiesOpen-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: vepdegestrant, Samuraciclib | Breast Cancer | 11 | 2026-12-31 | in 134 d | 2026-05-06 |
| TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)NCT05573555Phase 1b: Number of Participants With Dose Limiting ToxicitiesOpen-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: ARV-471, Ribociclib | Breast Cancer | 20 | 2026-12-30 | in 133 d | 2026-03-09 |
| Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerNCT05909397Study Lead-in (SLI): Incidence of Grade 4 neutropeniaRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Vepdegestrant (ARV-471/PF-07850327), Letrozole · Combination product: Palbociclib, Palbociclib | Breast Cancer | 59 | 2026-12-30 | in 133 d | 2026-02-10 |
| A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast CancerNCT06495164observationalOverall Survival (OS) | — | Active, not recruiting | Drug: Palbociclib, Aromatase inhibitor, Ribociclib, Abemaciclib | Breast Cancer, Malignant Neoplasm of Breast | 1 | 2026-12-30 | in 133 d | 2025-11-25 |
| Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)NCT06613984observationalNumber of subjects with Solicited adverse events | — | Active, not recruiting | Biological: Bretovameran | COVID-19 Vaccination | 660 | 2026-12-30 | in 133 d | 2026-01-14 |
| Lorlatinib Continuation StudyNCT05144997Number of participants with adverse events leading to permanent discontinuation of study interventionOpen-label · Treatment | Phase 4 | Active, not recruiting | Drug: Lorlatinib | Non-Small-Cell Lung Cancer, NSCLC | 76 | 2026-12-28 | in 131 d | 2025-12-17 |
| A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).NCT06551324Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: PF-06821497, Docetaxel, Enzalutamide | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | 600 | 2026-12-28 | in 131 d | 2026-08-11 |
| A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.NCT07219615Change from baseline in Urticaria Activity Score 7 (UAS7) at Week 12Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg | Chronic Spontaneous Urticaria | 200 | 2026-12-25 | in 128 d | 2026-06-17 |
| A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six MonthsNCT06622109observationalPercentage of Participants Reporting Adverse Reactions(ADRs) | — | Active, not recruiting | Biological: 20-valent Pneumococcal Conjugate Vaccine | Pneumococcal Disease | 1,100 | 2026-12-15 | in 118 d | 2026-03-12 |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2NCT04879329Confirmed Objective Response Rate (cORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) by blinded independent central review (BICR) (Cohorts A, B, C, and G)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: disitamab vedotin, pembrolizumab | Urothelial Carcinoma | 372 | 2026-12-11 | in 114 d | 2026-07-22 |
| A Study to Learn About How Different Forms of Study Medicine Prifetrastat Are Taken Up Into the Blood in Healthy AdultsNCT07721402Area under the Plasma Concentration-Time profile from time 0 to extrapolated infinite time (AUCinf) of Reference treatment of prifetrastat (AUClast If data does not permit AUCinf)Randomized · Open-label · Basic science | Phase 1 | Recruiting | Drug: prifetrastat Reference, prifetrastat Test 1, prifetrastat Test 2 | Healthy Participant | 32 | 2026-12-08 | in 111 d | 2026-07-23 |
| A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver FunctionNCT07231991Maximum observed concentration (Cmax) for vepdegestrantNon-randomized · Open-label · Other | Phase 1 | Recruiting | Drug: vepdegestrant | Healthy Participants | 24 | 2026-12-04 | in 107 d | 2026-04-03 |
| A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease VaccineNCT07500506Percentage of participants reporting prespecified local reactionsRandomized · Triple-masked · Prevention | Phase 3 | Recruiting | Biological: VLA15, Placebo | Lyme Disease | 1,712 | 2026-12-04 | in 107 d | 2026-05-06 |
| A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779Radiographic Progression Free Survival (rPFS)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: PF-06821497, Placebo, Enzalutamide | Metastatic Castration-Resistant Prostate Cancer | 900 | 2026-12-02 | in 105 d | 2026-08-14 |
| A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia AreataNCT07029711For US and Countries Following US Analysis Plan: Response based on achieving an absolute Severity of Alopecia Tool (SALT) score ≤20.Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Ritlecitinib higher dose, Ritlecitinib lower dose, Placebo | Severe Alopecia Areata | 208 | 2026-12-02 | in 105 d | 2026-06-17 |
| Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic CosmosNCT07673081observationalIncidence of RSV-related Acute Respiratory Infection (ARI) hospitalization | — | Not yet recruiting | — | Respiratory Syncytial Virus (RSV) | 293,334 | 2026-11-30 | in 103 d | 2026-06-29 |
| A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual MigraineNCT06641466Mean change from the Observation Period in number of migraine days per 5-day perimenstrual period across each cycle of the Double-Blind Treatment PhaseRandomized · Quadruple-masked · Prevention | Phase 3 | Recruiting | Drug: Rimegepant, Placebo Comparator, Standard of Care, Rimegepant | Menstrual Migraine | 723 | 2026-11-29 | in 102 d | 2026-07-09 |
| Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National DatasetNCT07235397observationalPCR-confirmed RSV-associated LRTD hospitalization occurring ≤180 days after birth (first episode) | — | Not yet recruiting | Biological: ABRYSVO | Respiratory Syncytial Virus Infections | 1 | 2026-11-13 | in 86 d | 2026-07-01 |
| Safety and Efficacy of Xalkori ROS1NCT03375242observationalThe incidence of adverse drug reactions in this surveillance. | — | Active, not recruiting | Drug: crizotinib | Non-small Cell Lung Cancer | 97 | 2026-11-06 | in 79 d | 2026-03-30 |
| A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and OlderNCT06782282observationalWeighted PCV20 vaccine effectiveness (VE) against Invasive Pneumococcal Disease (IPD) | — | Active, not recruiting | — | Community-Acquired Pneumonia (CAP) | 22,234,435 | 2026-10-30 | in 72 d | 2026-04-22 |
| A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisNCT05995964The number of participants achieving ≥75% improvement in EAS175 from baseline at week16.Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: PF-07275315, PF-07264660 · Other: Placebo | Atopic Dermatitis | 340 | 2026-10-19 | in 61 d | 2026-05-04 |
| A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.NCT06447662Part 1 & 2: Incidence of Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: PF-07934040 · Combination product: Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab | Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung | 64 | 2026-10-09 | in 51 d | 2026-07-22 |
| Impact and Effectiveness of ABRYSVO® Vaccination During PregnancyNCT06647654observationalRSV-associated LRTD hospitalization among infants | — | Active, not recruiting | Biological: ABRYSVO | Respiratory Syncytial Virus, Respiratory Tract Diseases | 1 | 2026-10-01 | in 43 d | 2026-05-15 |
| Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic ArthritisNCT05754710observationalNumber of patients with treatment emergent treatment-related adverse events | — | Recruiting | Drug: Xeljanz | Psoriatic Arthritis, Juvenile, Polyarticular Juvenile Idiopathic Arthritis | 10 | 2026-09-30 | in 42 d | 2026-08-03 |
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsNCT04557449Number of participants with dose limiting toxicities in the Dose Escalation PortionNon-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: PF-07220060, Midazolam · Combination product: Letrozole, Fulvestrant, Enzalutamide | Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung | 362 | 2026-09-23 | in 35 d | 2025-10-01 |
| Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth HormoneNCT05509894observationalIncidence of adverse events (AEs) | — | Active, not recruiting | Drug: Ngenla | Pediatric Growth Hormone Deficiency | 565 | 2026-09-23 | in 35 d | 2026-01-27 |
| Korean Post-marketing Surveillance for Xeljanz XRNCT04876781observationalNumber of Participants With Treatment Emergent Adverse Events (AEs) | — | Recruiting | Drug: Tofacitinib XR | Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis | 200 | 2026-09-22 | in 34 d | 2026-08-03 |
| A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India.NCT06587035observationalNumber of adverse events in participants on Somatrogon | — | Recruiting | Drug: Somatrogon | Dwarfism, Pituitary | 50 | 2026-09-21 | in 33 d | 2026-08-14 |
| A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without DiabetesNCT06924320Occurrence of treatment-emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Recruiting | Drug: MET233 and MET097, MET097 · Other: Placebo | Obesity and Obesity-related Medical Conditions | 381 | 2026-09-15 | in 27 d | 2026-06-01 |
| A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding WomenNCT07153159Area under the etrasimod concentration-time curve in breast milkNon-randomized · Open-label · Basic science | Phase 1 | Recruiting | Drug: Etrasimod | Healthy Participant | 8 | 2026-09-12 | in 24 d | 2026-04-07 |
| A Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy AdultsNCT07731100Area under the concentration-time curve from time zero to extrapolated infinite time (AUCinf) for PrifetrastatRandomized · Open-label · Basic science | Phase 1 | Not yet recruiting | Drug: Prifetrastat | Healthy Adults | 12 | 2026-09-10 | in 22 d | 2026-07-28 |
| A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy AdultsNCT07597928Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)Randomized · Open-label · Basic science | Phase 1 | Recruiting | Drug: PF-08049820, Rabeprazole | Healthy Adults, Healthy | 24 | 2026-09-03 | in 15 d | 2026-06-15 |
| A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial HypertensionNCT06137742Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Randomized · Quadruple-masked · Basic science | Phase 1/2 | Active, not recruiting | Drug: PF-07868489, Placebo for PF-07868489 | Pulmonary Arterial Hypertension | 97 | 2026-09-02 | in 14 d | 2026-05-19 |
| TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)NCT05548127Phase 1b: number of participants with dose limiting toxicitiesOpen-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: ARV-471, Abemaciclib | Breast Cancer | 37 | 2026-09-01 | in 13 d | 2026-02-10 |
| A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.NCT07543380Percentage of participants reporting prompted local reactions within 7 days following investigational product administrationOpen-label · Prevention | Phase 3 | Recruiting | Biological: RSVpreF | Respiratory Syncytial Virus (RSV) | 130 | 2026-08-31 | in 12 d | 2026-06-02 |
| A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy AdultsNCT07594769Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUCinf) of the test and reference formulationsRandomized · Open-label · Other | Phase 1 | Recruiting | Drug: ODT2 Test formulation, ODT Reference formulation | Migraine | 36 | 2026-08-31 | in 12 d | 2026-06-10 |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)NCT06152575Progression free survival per International Myeloma Working Group criteriaRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib | Multiple Myeloma | 492 | 2026-08-30 | in 11 d | 2026-08-14 |
| A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLCNCT07556549observationalAge at Start of Lorlatinib Treatment | — | Active, not recruiting | Drug: Lorlatinib | Non-Small Cell Lung Cancer ALK-positive | 50 | 2026-08-30 | in 11 d | 2026-08-10 |
| A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid TumorsNCT05262400Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycleNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: PF-07220060 + PF-07104091 combination dose escalation, PF-07220060 + PF-07104091 combination dose escalation, PF-07220060 + PF-07104091 combination dose escalation, PF-07220060 + PF-07104091 combination dose escalation, PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion, PF-07104091 + PF-07220060 + fulvestrant dose expansion, PF-07104091 + PF-07220060 + letrozole dose expansion, PF-07220060 + PF-07104091 combination dose escalation, PF-07220060 + PF-07104091 combination dose escalation, PF-07220060 + PF-07104091 combination dose escalation | Breast Cancer, Solid Tumors | 192 | 2026-08-23 | in 4 d | 2024-11-18 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy AdultsNCT06965465Number of participants with treatment emergent adverse events.Randomized · Triple-masked · Treatment | Phase 1 | Active, not recruiting | Biological: PF-07999415 · Drug: Placebo | Healthy | 32 | 2026-08-21 | in 2 d | 2026-07-23 |
| A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fasting ConditionsNCT07587697Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of tafamidisRandomized · Open-label · Basic science | Phase 1 | Active, not recruiting | Drug: Tafamidis, Tafamidis, Tafamidis | Healthy Adults | 15 | 2026-08-03 | — | 2026-06-03 |
| Consistency of Response With Rimegepant in Acute Treatment of MigraineNCT06898047observationalTime to Meaninful Pain Relief (MPR) post-dosing | — | Active, not recruiting | Drug: Rimegepant for acute migraine treatment | Migraine | 250 | 2026-07-31 | — | 2026-05-07 |
| Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis PopulationNCT07177209observationalProportion of patients that achieve early control of inflammation on conventional therapeutics within 6-24 months of UC diagnosis. | — | Active, not recruiting | Drug: Non-Interventional Study | Ulcerative Colitis | 4,000 | 2026-07-31 | — | 2026-05-14 |
| A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting PneumoniaNCT07251465observationalPCV20 vaccine effectiveness (VE) against all-cause pneumonia (ACP) calculated as (1- adjusted hazard ratio [aHR]) × 100% among adults aged ≥18-64 years with medical conditions and behavioral risk factors and among adults ≥65 years old, combined | — | Active, not recruiting | Biological: Receipt of PCV20 | Pneumonia | 846,279 | 2026-07-31 | — | 2026-06-22 |
| A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First TreatmentNCT07567352observationalOverall Treatment Duration of 1L Lorlatinib | — | Active, not recruiting | Drug: lorlatinib | Non-Small-Cell Lung, ALK-positive Advanced NSCLC, ALK-positive Non-small-cell Lung Cancer, ALK-positive NSCLC | 200 | 2026-07-31 | — | 2026-05-12 |
| EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe DiseaseNCT05261139Cohort 1-2: Maximum Observed Plasma Concentration (Cmax) of nirmatrelvir and ritonavirNon-randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: nirmatrelvir, ritonavir | COVID-19 | 160 | 2026-07-30 | — | 2025-07-17 |
| A Study to Understand What the Body Does to the Study Medicine Called PF-07799544 When Taken by Healthy AdultsNCT07578636Total recovery (%) of radioactivity in urine, feces and vomitus (if any), expressed as a percent of total oral radioactive dose administered.Non-randomized · Open-label · Basic science | Phase 1 | Active, not recruiting | Drug: Oral [14C] PF-07799544, Oral Unlabeled PF-07799544, IV [14C] PF-07799544 | Healthy Male Volunteers | 9 | 2026-07-02actual | — | 2026-07-28 |
| A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative ColitisNCT06294925observationalProportion of patients with symptomatic remission | — | Recruiting | Drug: Etrasimod | Colitis, Ulcerative | 360 | 2026-06-30 | — | 2026-06-22 |
| A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in GermanyNCT07494656observationalOverall Survival in Individuals With Incident Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Overall and in Those With at Least One Tafamidis Prescription | — | Active, not recruiting | Other: tafamidis 61mg (based on prescription data) | ATTR-CM (Transthyretin Amyloid Cardiomyopathy) | 1 | 2026-06-30 | — | 2026-05-22 |
| A Study to Learn if a Medicine Called Itraconazole Changes How the Body Processes the Study Medicine PF-08642534 in Healthy Adults.NCT07575945PF-08642534 Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)Non-randomized · Open-label · Basic science | Phase 1 | Active, not recruiting | Drug: PF-08642534, Itraconazole | Healthy Participant | 14 | 2026-06-26 | — | 2026-06-15 |
| A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal CancerNCT05217446Progression-free Survival (PFS)Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Encorafenib · Biological: Cetuximab, Pembrolizumab | Metastatic Colorectal Cancer | 108 | 2026-06-19actual | — | 2026-07-31 |
| Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy ParticipantsNCT07215078Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: atirmociclib (PF-07220060) | Healthy Volunteer | 72 | 2026-06-03 | — | 2025-11-28 |
| Swedish Ibrance Registries Insights (SIRI)NCT04654208observationalProportion of patients on treatment | — | Recruiting | Drug: palbociclib | Malignant Neoplasm of Breast | 1,500 | 2026-05-31 | — | 2026-03-31 |
| A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerNCT06012435Overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: sigvotatug vedotin, docetaxel | Carcinoma, Non-Small-Cell Lung | 762 | 2026-05-18actual | — | 2026-07-23 |
| A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2NCT06003231Confirmed Objective Response Rate (ORR) per Response Evaluation in Solid Tumors version 1.1 (RECIST v1.1) by investigator assessmentOpen-label · Treatment | Phase 2 | Active, not recruiting | Drug: disitamab vedotin | Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms | 120 | 2026-03-27actual | — | 2026-07-22 |
| Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsNCT03485209Confirmed Objective Response Rate (ORR) (Parts A, B, C, D, E, F, and G)Non-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: tisotumab vedotin, pembrolizumab, carboplatin, cisplatin | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck | 350 | 2026-03-20actual | — | 2026-07-22 |
| A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple MyelomaNCT05675449Part 1 Number of participants with dose limiting toxicity (DLT)Randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Elranatamab, Carfilzomib, Maplirpacept | Multiple Myeloma | 59 | 2026-03-11actual | — | 2026-08-13 |
| A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsNCT05020236Part 1 Safety Lead-In: Incidence of dose limiting toxicitiesRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Elranatamab, Daratumumab, Pomalidomide, Dexamethasone | Multiple Myeloma | 893 | 2026-02-26actual | — | 2026-08-14 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy AdultsNCT06686797Number of Participants With Treatment Emergent Adverse Events (TEAEs)Randomized · Double-masked · Basic science | Phase 1 | Active, not recruiting | Drug: PF-08049820, Placebo | Healthy | 71 | 2026-02-23 | — | 2026-02-03 |
| A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)NCT07335419Area under the concentration-time curve from time zero to extrapolated infinite time (AUCinf) for PF-07248144Non-randomized · Open-label · Basic science | Phase 1 | Active, not recruiting | Drug: PF-07248144, Itraconazole | Healthy Adult Participants | 12 | 2026-02-22actual | — | 2026-03-19 |
| Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCNCT04821622radiological Progression-Free SurvivalRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: talazoparib plus enzalutamide, Placebo plus enzalutamide | Prostate Cancer | 599 | 2026-02-18actual | — | 2026-08-17 |
| Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCLNCT04404283Overall survival (OS)Randomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Brentuximab vedotin, Rituximab, Lenalidomide · Other: Placebo | Diffuse Large B-cell Lymphoma | 239 | 2026-01-23actual | — | 2026-07-22 |
| A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaNCT04657991Safety Lead In (SLI): Incidence of Dose Limiting Toxicities (DLTs)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Encorafenib, Binimetinib, Pembrolizumab | Melanoma | 257 | 2026-01-12actual | — | 2026-04-07 |
| A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentNCT06105632Progression-Free Survival (PFS) progression, as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus, Exemestane | Advanced or Metastatic Breast Cancer | 333 | 2026-01-12actual | — | 2026-02-13 |
| A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or OverweightNCT06973720Percent change from baseline in body weight at Week 28Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: MET097, Placebo | Obesity, Overweight or Obesity | 268 | 2025-12-16actual | — | 2026-05-29 |
| A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female ParticipantsNCT07190430Pharmacokinetics (PK): Area Under the curve (AUC) of MidazolamNon-randomized · Open-label · Basic science | Phase 1 | Active, not recruiting | Drug: PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet | Atopic Dermatitis | 16 | 2025-12-15 | — | 2025-12-09 |
| A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.NCT07284173Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of PF-08049820.Open-label · Basic science | Phase 1 | Active, not recruiting | Drug: PF-08049820, Rabeprazole | Healthy Adults | 18 | 2025-12-15 | — | 2025-12-16 |
| A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerNCT05132582Progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Tucatinib, Trastuzumab, Pertuzumab, Combination product: Trastuzumab + Pertuzumab, Placebo | HER2 Positive Breast Cancer | 654 | 2025-09-05actual | — | 2026-07-22 |
| A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.NCT06206837Phase 1b: Number of Participants With Dose Limiting ToxicitiesOpen-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: vepdegestrant, PF-07220060 | Breast Cancer | 71 | 2025-09-05actual | — | 2026-02-27 |
| A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal CancerNCT04607421results2026-06-11SLI: Number of Participants With Dose Limiting Toxicity (DLTs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Encorafenib, Cetuximab, Oxaliplatin, Irinotecan, Leucovorin, 5-FU, Capecitabine, Bevacizumab | Neoplasms | 841 | 2025-03-01actual | — | 2026-06-11 |
| A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerNCT05654623results2026-02-03Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized ParticipantsRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: ARV-471, Fulvestrant | Advanced Breast Cancer | 624 | 2025-01-31actual | — | 2026-03-18 |
| A Study of Sasanlimab in People With Non-muscle Invasive Bladder CancerNCT04165317results2026-01-22Cohort A: Event Free Survival (EFS) as Assessed by the Investigator: Arm A Versus Arm CRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: PF-06801591, Bacillus Calmette-Guerin | Non-muscle Invasive Bladder Cancer | 1,068 | 2024-12-02actual | — | 2026-01-22 |
| Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid TumorsNCT03709680Phase 2 open-label, randomized: Event-free survival (EFS) based on Investigator assessment.Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Palbociclib, Temozolomide, Irinotecan, Topotecan, Cyclophosphamide | Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma | 128 | 2024-08-26actual | — | 2025-01-14 |
| Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersNCT04430738results2025-09-09Number of Participants With Renal Dose-Limiting Toxicities (DLTs): Phase 1b (Cohort 1A and 1B)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Active, not recruiting | Drug: tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab | Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma | 40 | 2024-07-31actual | — | 2026-02-24 |
| Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A AdultsNCT04370054results2025-08-17Total Annualized Bleeding Rate (ABR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Biological: PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy | Hemophilia A | 77 | 2024-06-17actual | — | 2026-08-19 |
| Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular DystrophyNCT04281485results2025-06-08Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Score at Week 52Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Genetic: PF-06939926, PF-06939926 · Other: Placebo, Placebo | Duchenne Muscular Dystrophy | 114 | 2024-05-15actual | — | 2026-07-22 |
| Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsNCT04579380results2024-11-13Confirmed Objective Response Rate (cORR) as Assessed by InvestigatorOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Active, not recruiting | Drug: tucatinib, trastuzumab, fulvestrant | Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms | 217 | 2023-11-01actual | — | 2025-12-19 |
| A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)NCT04721977results2024-08-09Confirmed Objective Response Rate(cORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Determined by Independent Central Review (ICR): Japanese ParticipantsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Active, not recruiting | Drug: Tucatinib, Capecitabine · Biological: Trastuzumab | Breast Cancer | 66 | 2023-07-17actual | — | 2026-01-09 |
| A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerNCT03975647results2024-07-30Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator AssessmentRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: tucatinib, placebo, T-DM1 | HER2-positive Breast Cancer | 466 | 2023-06-29actual | — | 2026-07-23 |
| A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)NCT05463952results2024-09-23Number of Participants With Dose Limiting Toxicity (DLTs) During First Treatment CycleOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Active, not recruiting | Drug: vepdegestrant | Breast Neoplasms | 6 | 2023-05-04actual | — | 2024-11-13 |
| Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)NCT02319837results2024-03-25Metastasis-free Survival (MFS) Compared Between Enzalutamide Plus Leuprolide and Placebo Plus LeuprolideRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label | Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate | 1,068 | 2023-01-31actual | — | 2026-07-09 |
| A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia BNCT03861273results2024-03-27Annualized Bleeding Rate (ABR) for Total Bleeds (Treated and Untreated) From Week 12 to Month 15Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Biological: PF-06838435/ fidanacogene elaparvovec | Hemophilia B | 51 | 2022-11-16actual | — | 2026-06-01 |
| Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPCNCT03395197results2024-01-17Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Occuring Within the First 66 Days of Dosing - Part 1Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Talazoparib with enzalutamide, Placebo with enzalutamide | mCRPC | 1,054 | 2022-10-03actual | — | 2026-08-17 |
| MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAbNCT04649359results2023-10-25Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) CriteriaNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Active, not recruiting | Drug: Elranatamab (PF-06863135) | Multiple Myeloma | 187 | 2022-06-17actual | — | 2026-05-19 |
| A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCNCT03052608results2021-04-01Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) AssessmentRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Lorlatinib, Crizotinib | Carcinoma, Non-Small-Cell Lung | 296 | 2020-03-20actual | — | 2025-11-25 |
| A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult ParticipantsNCT06103734Comparing efficacy of zavegepant with placebo in the acute treatment of migraine as measured by pain freedom at 2-hours post dose during the Double-Blind Treatment (DBT) Phase.Randomized · Triple-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Strategic decision to cancel the study based on adjusted clinical development plan. | Combination product: Zavegepant 10 mg, Placebo - Control 1, Placebo - Control 2 | Migraine | 0 | 2027-08-02 | in 348 d | 2026-01-13 |
| A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.NCT06075615observationalThe real-world intracranial overall response rate (rwICORR) at Month 3 | — | Withdrawnsponsor's stated reason: Sponsor Decision | Drug: dacomitnib | Carcinoma, Non-Small-Cell Lung | 0 | 2026-09-07 | in 19 d | 2025-02-07 |
| Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia BNCT03307980Incidence of PF-06838435 related adverse eventsOpen-label · Treatment | Phase 2 | Completed | Biological: PF-06838435 (formerly SPK-9001) | Hemophilia B | 21 | 2026-07-23actual | — | 2026-08-11 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body in Healthy AdultsNCT07235150Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE)Randomized · Double-masked · Basic science | Phase 1 | Terminatedsponsor's stated reason: The estimated benefit-risk profile of PF-07985631 is not anticipated to be favorable in the expected population to be treated | Drug: PF-07985631, Placebo | Healthy | 9 | 2026-07-16actual | — | 2026-08-18 |
| A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults.NCT07575906Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Randomized · Double-masked · Basic science | Phase 1 | Completed | Drug: PF-08057418 · Other: Placebo (A placebo does not have any medicine in it but looks just like the medicine being studied.) | Healthy | 8 | 2026-07-16actual | — | 2026-07-24 |
| A Study to Understand How a Study Medicine Called PF-07328948 is Absorbed and Processed in the Body of Healthy Male AdultsNCT07508228Total recovery of radioactivity in urine, feces, expired air (if analyzed and if reportable), and emesis (if any), and all routes combined, expressed as a percentage of oral radioactive dose administered.Non-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Oral [14C]PF-07328948, Oral Unlabeled PF-07328948, IV [14C]PF-07328948 | Healthy | 8 | 2026-07-10actual | — | 2026-08-06 |
| A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or ObesityNCT07400679Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of PF-08653944Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: PF-08653944 | Overweight, Obesity, Healthy | 48 | 2026-07-02actual | — | 2026-08-17 |
| A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin (Somatropin) Delivery and Taken up Into the Blood in Healthy AdultsNCT07542886Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUCinf) of SomatropinRandomized · Open-label · Basic science | Phase 1 | Completed | Device: Marketed Genotropin Pen 12, New Genotropin Injector Pen · Drug: Genotropin 4mg | Healthy | 27 | 2026-06-25actual | — | 2026-08-10 |
| Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544NCT07563894Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-07799933 Form 1 tablet when dosed in combination with PF-07799544 fastedRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: PF-07799933 tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fed, PF-07799933 film-coated tablets fasted, PF-07799933 film-coated tablets following rabeprazole pretreatment fasted | Healthy | 16 | 2026-06-24actual | — | 2026-07-09 |
| Anticoagulation in Patients With Venous Thromboembolism and CancerNCT04618913observationalRecurrence of Thromboembolism | — | Completed | Drug: Apixaban, Rivaroxaban, Edoxaban, Dabigatran, VKA, LMWH | Neoplasms, Embolism | 1 | 2026-06-22actual | — | 2026-07-24 |
| Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)NCT06353087observationalPercentage of Participants Achieving >= 75% Improvement From Baseline in Eczema Area and Severity Index (EASI-75) Response at Week 2, 12, 52 | — | Completed | — | Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases, Immune System Diseases, Janus Kinase Inhibitors | 41 | 2026-06-22actual | — | 2026-08-18 |
| A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of IbuzatrelvirNCT07552779Plasma ibuzatrelvir AUCinf (as data permit, otherwise AUClast) in the fasted stateRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Ibuzatrelvir co-process API film coated tablet, Ibuzatrelvir filmcoated tablet | Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), COVID-19 (Coronavirus Disease 2019), Upper Respiratory Tract Infections, Respiratory Tract Infection, Respiratory Tract Diseases, COVID-19, COVID-19 Infection, COVID-19 SARS-CoV-2 Infection, Pneumonia, Lung Diseases | 17 | 2026-06-03actual | — | 2026-07-28 |
| A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid TumorsNCT05571839Number of participants with adverse events (AEs)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety concerns. | Drug: PF-08046049 | Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma | 41 | 2026-06-01actual | — | 2026-07-01 |
| A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related DiseasesNCT05742217observationalReal-World Overall Response Rate (ORR) for each TCR MM therapy | — | Completed | — | Relapse Multiple Myeloma, Refractory Multiple Myeloma | 121 | 2026-05-31actual | — | 2026-07-09 |
| Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims DataNCT05876377observationalAim 1: Any PCC-related diagnosis not present before the COVID-19 diagnosis | — | Completed | Biological: Pfizer-BioNTech COVID-19 mRNA vaccine | SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome | 1 | 2026-05-31actual | — | 2026-06-30 |
| High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in FranceNCT05038228observationalBleeding leading to hospitalization | — | Completed | Drug: Apixaban, Rivaroxaban, Dabigatran, Vitamin K antagonist (VKA) | Atrial Fibrillation | 1 | 2026-05-29actual | — | 2026-06-30 |
| A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19NCT07089680observationalComposite outcome of progression to severe disease or all-cause mortality within 30 days | — | Completed | Drug: Nirmatrelvir/Ritonavir | Coronavirus Disease 2019 (COVID-19) | 937 | 2026-05-29actual | — | 2026-08-14 |
| A Study of SGN-MesoC2 in Advanced Solid TumorsNCT06466187Number of participants with adverse events (AEs)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Drug: PF-08052666 | Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial | 19 | 2026-05-27actual | — | 2026-07-07 |
| An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.NCT07527832observationalIncidence rate of "haemorrhage" | — | Completed | Drug: Bevacizumab-Pfizer Biosimilar, Avastin | Colorectal Cancer | 1,000 | 2026-05-27actual | — | 2026-06-03 |
| A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in AdultsNCT06182124Percentage of participants reporting prespecified local reactions within 7 days after vaccinationRandomized · Triple-masked · Prevention | Phase 1/2 | Completed | Biological: Multivalent Pneumococcal Vaccine - Formulation 1, Multivalent Pneumococcal Vaccine - Formulation 2, 20-valent pneumococcal conjugate vaccine (20vPnC), Licensed pneumococcal comparator vaccine, Multivalent Pneumococcal Vaccine - Formulation 3, Multivalent Pneumococcal Vaccine - Formulation 4 | Pneumococcal Disease | 1,363 | 2026-05-12actual | — | 2026-06-10 |
| A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.NCT06704724Part 1 & 2: Incidence of Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns. | Drug: PF-07985045 · Combination product: Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, Sasanlimab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, PF-07284892 | Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung | 30 | 2026-05-12actual | — | 2026-05-22 |
| A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fed ConditionsNCT07470866Area under the concentration-time curve (AUCinf)Randomized · Open-label · Basic science | Phase 1 | Terminatedsponsor's stated reason: The study was terminated for business reasons; there were no safety concerns. | Drug: Tafamidis (Reference), Tafamidis (Test) | Healthy | 24 | 2026-05-12actual | — | 2026-06-26 |
| A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced CancersNCT06870487Part A and Part B: Number of participants with dose limiting toxicities (DLTs) in dose escalationOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns | Drug: PF-08046032, Sasanlimab | Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer | 6 | 2026-04-23actual | — | 2026-05-08 |
| A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy AdultsNCT07261371Area under the Plasma Concentration-Time profile from time 0 extrapolated to infinite time (AUCinf) of the test and reference formulationsRandomized · Open-label · Other | Phase 1 | Completed | Drug: Test formulation (Treatment A), Reference formulation (Treatment B), Test formulation (Treatment C), Test formulation (Treatment D) | Healthy Volunteer | 64 | 2026-04-22actual | — | 2026-05-04 |
| A Study of MET233 in Individuals With Obesity or OverweightNCT07022977Occurrence of Treatment Emergent Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: MET233, Placebo | Obesity and Overweight | 144 | 2026-04-21actual | — | 2026-05-26 |
| A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid TumorsNCT05983133Number of participants with adverse events (AEs)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Drug: PF-08046052 | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma | 68 | 2026-04-16actual | — | 2026-05-05 |
| A Study to Learn About How the Body Processes the Study Medicine Called PF-07328948 in Healthy Chinese AdultsNCT07455240Maximum Observed Plasma Concentration (Cmax)Open-label · Other | Phase 1 | Completed | Drug: PF-07328948 | Healthy Participant | 10 | 2026-04-15actual | — | 2026-04-23 |
| Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.NCT05905341Part 1: First cycle dose limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: This decision was based on business considerations and not due to specific safety reasons or a request from a regulatory authority. | Drug: PF-07224826, PF-07224826, PF-07224826, PF-07224826, PF-07224826, PF-07224826, PF-07224826 · Combination product: Fulvestrant, Fulvestrant, Fulvestrant, Fulvestrant, Fulvestrant, Fulvestrant, Fulvestrant | Breast Cancer, Ovarian Cancer, Liposarcoma, Non-small Cell Lung Cancer (NSCLC), Endometrial, Solid Tumors | 0 | 2026-04-14 | — | 2023-11-08 |
| A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.NCT06678555observationalreal-world progression-free survival | — | Completed | Drug: Lorlatinib | Carcinoma, Non-Small-Cell Lung | 22 | 2026-04-14actual | — | 2026-07-10 |
| A Safety Study of PF-08046044/SGN-35C in Adults With Advanced CancersNCT06254495Number of participants with adverse events (AEs)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons due to portfolio reprioritization. The decision was not based on any safety or regulatory concerns | Drug: PF-08046044/SGN-35C | Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic | 58 | 2026-04-13actual | — | 2026-07-06 |
| A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.NCT05896163Phase 1b: Number of participants with Dose limiting toxicities (DLT)Randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Business/Administrative decision to pursue other programs/assets within the oncology portfolio. Not due to any detected safety signals or requests from regulatory authorities. | Drug: maplirpacept (PF-07901801), Glofitamab, Obinutuzumab | Diffuse Large B-Cell Lymphoma | 40 | 2026-04-09actual | — | 2026-05-06 |
| Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid CardiomyopathyNCT06393465observationalRate of neurologic disease progression | — | Completed | Drug: Tafamidis | Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) | 50 | 2026-04-07actual | — | 2026-04-29 |
| A Study to Learn How Different Forms of the Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy AdultsNCT07231978Pharmacokinetics: Area under the plasma concentration (AUC) of prazosinRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Prazosin HCl | Healthy | 69 | 2026-04-03actual | — | 2026-05-14 |
| A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder CancerNCT07386847observationalReal world Progression Free Survival (rwPFS) | — | Completed | — | Metastatic Urothelial Carcinoma, Urothelial Cancer, Urothelial Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma | 1 | 2026-03-30actual | — | 2026-05-28 |
| A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic MalignanciesNCT06974734Number of participants with adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns | Drug: PF-08046037, sasanlimab | Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN) | 8 | 2026-03-20actual | — | 2026-04-23 |
| Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical CancerNCT03786081Dose escalation: Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor has decided to stop the trial based on strategic decisions | Drug: Tisotumab Vedotin, Bevacizumab, Pembrolizumab, Carboplatin | Cervical Cancer | 214 | 2026-03-19actual | — | 2026-07-22 |
| Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the USNCT07226531observationalPatient demographics characteristics: race | — | Completed | Drug: Ritlecitinib | Alopecia Areata | 300 | 2026-03-06actual | — | 2026-08-10 |
| SPECIAL INVESTIGATION FOR ABRYSVO IN PREGNANT WOMEN AND INFANTSNCT06482099observationalPercentage of pregnant women reporting Adverse Reactions for 28 days after vaccination | — | Completed | Biological: RSVpreF vaccine | Respiratory Tract Infection | 497 | 2026-02-27actual | — | 2026-04-09 |
| A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.NCT07261085observationalTime to the first severe composite outcome (all-cause hospital admission, ICU admission, or death) within 30 days of treatment assessment. | — | Completed | Drug: nirmatrelvir-ritonavir · Other: No treatment | COVID-19 | 99,000 | 2026-02-26actual | — | 2026-06-29 |
| A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid TumorsNCT06799533Number of participants with adverse events (AEs)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns. | Drug: PF-08046031 | Malignant Melanoma, Melanoma, Metastatic Melanoma, Solid Tumors | 11 | 2026-02-23actual | — | 2026-03-18 |
| A Study to Learn About How a New Pneumococcal Vaccine Works in ChildrenNCT06531538Percentage of participants reporting prespecified local reactions within 7 days after each doseRandomized · Triple-masked · Prevention | Phase 2 | Completed | Biological: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) | Pneumococcal Disease | 225 | 2026-02-09actual | — | 2026-03-11 |
| A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) TranquilloNCT05583526US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and T-VASI50 at Week 52Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Ritlecitinib, Placebo | Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo | 607 | 2026-02-05actual | — | 2026-02-27 |
| Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsNCT04609566Confirmed objective response rate (ORR) based on investigator assessment using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) criteriaOpen-label · Treatment | Phase 2 | Completed | Drug: brentuximab vedotin, pembrolizumab | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck | 161 | 2026-02-03actual | — | 2026-07-06 |
| A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaNCT05926960Objective Response Rate (ORR) is defined as the proportion of participants in each treatment arm with a confirmed best overall response of either Complete Response (CR) or Partial Response (PR), as determined by investigator assessment per RECIST v1.1Randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Study terminated due to inability to recruit the target number of patients. There were no safety and/or efficacy concerns involved in the decision to stop enrollment. | Drug: encorafenib, binimetinib, pembrolizumab, ipilimumab, nivolumab | Melanoma | 38 | 2026-02-02actual | — | 2026-03-09 |
| A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese AdultsNCT07019909Percentage of participants reporting prompted local reactions within 7 days following investigational product administrationRandomized · Double-masked · Prevention | Phase 1 | Completed | Biological: 20vPnC, 13vPnC | Pneumococcal Disease | 400 | 2026-01-28actual | — | 2026-02-25 |
| A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of MalnutritionNCT07086664Number of Participants With Treatment Emergent Adverse EventsRandomized · Quadruple-masked · Basic science | Phase 1 | Terminatedsponsor's stated reason: The study was prematurely discontinued due to a business decision. The decision to terminate the study is not related to a safety concern. | Drug: Placebo, PF-07258669 | Healthy Volunteers | 7 | 2026-01-21actual | — | 2026-02-06 |
| Korea Post Marketing Surveillance (PMS) Study of VizimproNCT04721106observationalIncidence of adverse events categorized according to physical organ and disease/symptom | — | Completed | Drug: Vizimpro | Lung Neoplasms | 188 | 2026-01-19actual | — | 2026-02-10 |
| Post Marketing Surveillance (PMS) Study of Cresemba in Korea.NCT04744454observationalAdverse event (AE) as safety evaluation | — | Completed | Drug: Isauvuconazole group | Aspergillosis, Mucormycosis | 94 | 2026-01-13actual | — | 2026-04-13 |
| An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)NCT05477524Relative incidence rate reduction of confirmed Lyme disease cases in the VLA15 group compared to the placebo groupRandomized · Quadruple-masked · Prevention | Phase 3 | Completed | Biological: VLA15 · Other: Saline | Lyme Disease | 12,546 | 2026-01-07actual | — | 2026-06-04 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 Are Tolerated and Act in the Body in Healthy Adults.NCT07514156Number of Participants With Treatment Emergent Adverse Events (AEs)Randomized · Double-masked · Basic science | Phase 1 | Completed | Drug: PF-07940369, Placebo | Healthy Adults | 30 | 2026-01-06actual | — | 2026-04-07 |
| Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & BNCT06634836observationalFrequency of self-reported symptoms pre and post hemophilia gene therapy | — | Withdrawnsponsor's stated reason: Business decision | — | Hemophilia A, Hemophilia B | 0 | 2025-12-31 | — | 2025-08-29 |
| A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DMNCT06897202Percent change from baseline in body weight at Week 28 (Day 197)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: MET097 Injection, Placebo | Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM) | 133 | 2025-12-29actual | — | 2026-06-12 |
| A Study to Understand What the Body Does to the Study Medicine Called PF-07248144 When Taken by Healthy AdultsNCT07423286Total recovery of radioactivity in urine, feces and vomitus (if any) expressed as a percent of total radioactive dose administered.Open-label · Basic science | Phase 1 | Completed | Drug: Oral [14C] PF-07248144, Oral unlabeled PF-07248144, IV [14C] PF-07248144 | Healthy Adult Participants | 8 | 2025-12-28actual | — | 2026-02-20 |
| Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic DermatitisNCT03422822Treatment emergent adverse eventsRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo, Abrocitinib 100 mg, Abrocitinib 100 mg, Abrocitinib 200 mg | Dermatitis, Atopic | 3,166 | 2025-12-22actual | — | 2026-01-15 |
| A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144NCT07198035Maximum Observed Plasma Concentration (Cmax) Period 1Non-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: PF-07248144, Carbamazepine | Healthy Adults | 12 | 2025-12-17actual | — | 2026-04-03 |
| Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 YearsNCT04821310Proportion of patients with endoscopically confirmed maintenance of healing of erosive esophagitis at Week 24, considering patients with excessive use of rescue medication as treatment failuresRandomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Pfizer has made an internal business decision to terminate the B1791094 study. This decision was not due to safety concerns or requests from any regulatory authorities. | Drug: Full dose Pantoprazole plus matching placebo, Half Dose Pantoprazole plus matching placebo | Esophagitis | 43 | 2025-12-16actual | — | 2026-06-15 |
| A Safety Study of PF-08046045/SGN-35T in Adults With Advanced CancersNCT06120504Number of participants with adverse events (AEs)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Study terminated as part of strategic considerations | Drug: PF-08046045 | Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin | 22 | 2025-12-10actual | — | 2026-07-06 |
| A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy ParticipantsNCT06397144Area under curve (AUC) from time zero to 48 hours post dose (nirmatrelvir)Randomized · Open-label · Basic science | Phase 1 | Withdrawnsponsor's stated reason: Sponsor business decision to terminate study. Decision not due to major safety concerns or requests from any regulatory authorities. | Drug: Paxlovid, Paxlovid, Nirmatrelvir/ritonavir, Nirmatrelvir/ritonavir | Biological Availability, Healthy Participants | 0 | 2025-12-09 | — | 2025-12-26 |
| Tofacitinib in Adult Patients With Moderate to Severe Ulcerative ColitisNCT04424303observationalProportion of patients with clinical benefit one year after initiation of tofacitinib treatment. | — | Completed | Drug: Tofacitinib | Ulcerative Colitis | 152 | 2025-12-08actual | — | 2026-01-15 |
| A Study to Learn About the Study Medicine Called PF-07905428 in Healthy Participants and Participants With Acne VulgarisNCT06671834Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: PF-07905428, Placebo | Acne Vulgaris | 52 | 2025-12-04actual | — | 2025-12-30 |
| A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060NCT07160738Plasma PF-07220060 Maximum Observed Plasma Concentration (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: PF-07220060, Itraconazole, Probenecid | Healthy Adults | 25 | 2025-11-24actual | — | 2026-04-03 |
| A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese AdultsNCT07235137Maximum Observed Plasma Concentration (Cmax)Open-label · Basic science | Phase 1 | Completed | Drug: Ibuzatrelvir | Healthy Participant | 12 | 2025-11-21actual | — | 2026-01-07 |
| A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsNCT06549816Number of participants with adverse events (AEs)Open-label · Treatment | Phase 1 | Completed | Drug: sigvotatug vedotin | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 6 | 2025-11-18actual | — | 2025-12-15 |
| A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative ColitisNCT05549323Part A: Proportion of participants achieving clinical remission at Week 12 in participants with moderate to severe UC.Randomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study was terminated due to business decision. The decision to terminate the trial was not based on any safety concerns associated with PF-07054894. | Drug: PF-07054894, Placebo | Ulcerative Colitis | 44 | 2025-11-11actual | — | 2026-02-25 |
| Korean Regulatory Post Marketing Surveillance for SomavertNCT05131100observationalNumber of participants who experience adverse events | — | Completed | Drug: Somavert | Acromegaly | 11 | 2025-11-10actual | — | 2026-07-23 |
| A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell DiseaseNCT05348915Incidence of treatment-emergent adverse events (TEAEs).Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision to terminate study based on results of parent study GBT2104-131. | Drug: Inclacumab | Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease | 242 | 2025-11-07actual | — | 2025-12-17 |
| A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)NCT07086651observationalTreatment duration | — | Completed | Drug: Enzalutamide, Apalutamide | Metastatic Castration Sensitive Prostate Cancer (mCSPC), Cancer of the Prostate, Prostate Neoplasms, Prostate Cancer | 1,300 | 2025-10-31actual | — | 2025-12-08 |
| A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy ParticipantsNCT07130097Area under the Plasma Concentration-Time profile from time 0 to time of last quantifiable data point (AUClast)) of test and reference atirmociclib formulations after a high fat/high calorie meal (If data does not permit AUCinf)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: PF-07220060 | Healthy Participant | 35 | 2025-10-26actual | — | 2026-04-20 |
| A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy AdultsNCT06137729AE observed after single or multiple dosesRandomized · Double-masked · Basic science | Phase 1 | Terminatedsponsor's stated reason: Study was terminated early . This decision was not due to any safety concerns associated with PF-07899895 but rather due to a business decision. | Drug: PF-07899895, Placebo | Healthy | 37 | 2025-10-24actual | — | 2025-11-25 |
| Atrial Fibrillation Data Linkage Non-Interventional StudyNCT05810727observationalEvent Rate of Stroke/Systemic embolism (SE) | — | Completed | — | Atrial Fibrillation | 12,556 | 2025-10-23actual | — | 2025-11-20 |
| A Study to Learn About the Study Medicine Called PF-07976016 in Adults With ObesityNCT06717425Percent change from baseline in body weightRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: PF-07976016, Placebo | Obesity | 263 | 2025-10-23actual | — | 2026-02-06 |
| A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world DatabaseNCT06962969observationalNumber of participants with adverse events that occur during treatment | — | Completed | Drug: Ibrance | Advanced or Metastatic Breast Cancer | 1 | 2025-10-23actual | — | 2026-04-02 |
| A Study to Compare the Experiences of Taking Daily Growth Hormone Injections to Weekly Ngenla in Children With Low Levels of Growth HormoneNCT06113952observationalMean Adherence To Ngenla and daily growth hormone | — | Withdrawnsponsor's stated reason: company business-strategic decision | Device: Sharps bin to collect used needles/injections | Pediatric Growth Hormone Deficiency | 0 | 2025-10-17 | — | 2024-02-09 |
| A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NCT06321523observationalNumber of Participants With Change From Baseline in New York Heart Association (NYHA) Classification | — | Completed | Drug: Tafamidis 61 milligrams | Transthyretin Amyloid Cardiomyopathy | 13 | 2025-10-13actual | — | 2025-11-20 |
| A Study to Understand How the Body Processes [14C]PF-07104091 in Healthy ParticipantsNCT07127770Percentage of Total Radiocarbon (14c) excreted in urineOpen-label · Basic science | Phase 1 | Completed | Drug: PF-07104091 | Healthy Adults | 9 | 2025-10-08actual | — | 2025-12-19 |
| A Study to Learn if the Study Medicine Called Fluconazole Changes How the Other Body Processes the Study Medicine PF-07248144NCT07636018Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-07248144 - Period 1Open-label · Other | Phase 1 | Completed | Drug: PF-07248144, Fluconazole | Healthy Adults | 12 | 2025-10-08actual | — | 2026-06-09 |
| A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy AdultsNCT07172321Pharmacokinetics (PK): Plasma Area Under the Concentration Versus Time Curve (AUC) of PF-08049820 in the fasted stateRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: PF-08049820 MR1, PF-08049820 MR2, PF-08049820 IR | Atopic Dermatitis | 12 | 2025-10-04actual | — | 2025-11-17 |
| Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular DystrophyNCT05429372Incidence and severity of Treatment-Emergent Adverse Events and Serious Adverse EventsOpen-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: All participants who have received fordadistrogene movaparvovec in any Pfizer study will now be assessed for long-term safety in one combined study: C3391003 | Genetic: PF-06939926 | Muscular Dystrophy, Duchenne | 10 | 2025-10-03actual | — | 2025-10-21 |
| A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.NCT06546553PART 1: Number of participants with Dose-limiting toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Study terminated as part of strategic considerations and not based on safety concerns. | Drug: PF-07826390 · Biological: sasanlimab · Other: SOC (anti-PD-1 + platinum -based chemo) | Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma | 10 | 2025-10-03actual | — | 2026-02-23 |
| Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In SwedenNCT04338204observationalProportion of Participants in Remission as Measured by Partial Mayo Score | — | Completed | Drug: tofacitinib | Ulcerative Colitis | 102 | 2025-09-30actual | — | 2026-06-03 |
| A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in AdultsNCT06890416Geometric Mean Ratio (GMR) of Neutralizing Titer (NTs) for RSV A and B in RSVpreF + herpes zoster subunit vaccine (HZ/su) Compared to RSVpreF AloneRandomized · Open-label · Prevention | Phase 3 | Completed | Biological: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, HZ/su VACCINE | Respiratory Syncytial Virus (RSV) | 526 | 2025-09-30actual | — | 2025-11-06 |
| Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.NCT06961331observationalTime to Next Treatment | — | Completed | Drug: Tucatinib, Trastuzumab, Capecitabine | Metastatic HER2+ Advanced Breast Cancer | 86 | 2025-09-25actual | — | 2026-01-09 |
| A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.NCT05689164Number of participants with serious adverse eventsOpen-label · Other | Phase 3 | Terminatedsponsor's stated reason: All participants who have received fordadistrogene movaparvovec in any Pfizer study will now be assessed for long-term safety in 1 combined study: C3391003 | Biological: fordadistrogene movaparvovec | Duchenne Muscular Dystrophy | 7 | 2025-09-24actual | — | 2025-10-21 |
| A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy AdultsNCT05703607SSA: Percentage of participants reporting local reactionsRandomized · Quadruple-masked · Prevention | Phase 1/2 | Terminatedsponsor's stated reason: Strategic decision made by the company | Biological: Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection, Candidate 3: PF-07921186: VZV modRNA Suspension for Injection, Shingrix, Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection | Shingles, Herpes Zoster Infection, Human | 484 | 2025-09-23actual | — | 2026-05-04 |
| A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic InfluenzaNCT06179446Percentage of participants by age group reporting local reactionsRandomized · Quadruple-masked · Prevention | Phase 1 | Completed | Biological: pdmFlu vaccine, Placebo, Licensed influenza vaccine | Grippe, Influenza, Vaccines | 157 | 2025-09-23actual | — | 2026-02-23 |
| A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and TaiwanNCT05512819Percentage of participants in India and Taiwan with local reactions (redness, swelling, and pain at the injection site), separately by countryRandomized · Quadruple-masked · Prevention | Phase 3 | Completed | Biological: 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine | Pneumococcal Disease | 541 | 2025-09-20actual | — | 2025-12-15 |
| A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.NCT06321510observationalPercentage of patients with dacomitinib dosage change and reasons | — | Completed | — | Lung Cancer | 29 | 2025-09-19actual | — | 2026-05-29 |
| A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy AdultsNCT06661694Maximum Observed Plasma Concentration (Cmax) of Mevrometostat (Formulation 1)Randomized · Open-label · Other | Phase 1 | Withdrawnsponsor's stated reason: sponsor decision | Drug: Treatment A, Treatment B, Treatment C, Treatment D | Healthy | 0 | 2025-09-08 | — | 2025-04-24 |
| A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult ParticipantsNCT06712082Maximum Observed Plasma Concentration (Cmax)Randomized · Quadruple-masked · Other | Phase 1 | Completed | Drug: PF-07264660 · Other: Placebo | Healthy | 12 | 2025-09-04actual | — | 2025-09-25 |
| A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.NCT05810038Mean change from the Observation Phase (OP) in the number of migraine days per month over the entire Double Blind Treatment (DBT) PhaseRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Rimegepant, Placebo | Migraine | 787 | 2025-08-25actual | — | 2026-01-14 |
| A Study to Learn How Different Amounts and Forms of the Study Medicine Called PF-06414300 Act in Healthy AdultsNCT06659250Number of Adverse Events (AE) observed after single or multiple dosesRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: PF-06414300, Placebo | Healthy Participants | 63 | 2025-08-22actual | — | 2025-10-01 |
| A Study to Learn How the Study Medicine Called [14C]PF-07054894 is Processed by the BodyNCT07009353Cumulative recovery (%) of radioactivity in urine and feces (adjusted for vomitus, if any), expressed as a percent of total oral radioactive dose administered.Non-randomized · Single-masked · Treatment | Phase 1 | Completed | Drug: PF-07054894, PF-07054894 | Healthy | 10 | 2025-08-20actual | — | 2025-12-02 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy AdultsNCT06821750Number of Participants with Treatment Emergent Adverse Events Following Single DosesRandomized · Triple-masked · Other | Phase 1 | Terminatedsponsor's stated reason: The Sponsor has decided to terminate the above referenced clinical study for business reasons. There were no safety concerns that led to this decision and there was no impact to participant safety. | Biological: PF-07314470, Placebo for PF-07314470 | Healthy | 23 | 2025-08-18actual | — | 2025-10-22 |
| A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various CancerNCT04889495observationalSafety profile | — | Withdrawnsponsor's stated reason: The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea. | Drug: Zirabev | Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Metastatic Kidney Cancer, Cervical Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 0 | 2025-08-16 | — | 2025-03-19 |
| Safety and Efficacy of LorbrenaNCT03844464observationalIncidence of adverse drug reactions of central nervous system disorder and hepatic dysfunction | — | Completed | — | Non-small Cell Lung Cancer | 1,290 | 2025-07-30actual | — | 2025-09-04 |
| A Study Comparing Subcutaneous Injection of Sayana Press In the Upper Arm Versus Anterior Thigh and AbdomenNCT04893798Serum Trough Concentration (Ctrough) of MedroxyprogesteroneRandomized · Open-label · Other | Phase 1 | Completed | Combination product: Sayana Press | Healthy | 67 | 2025-07-24actual | — | 2025-08-14 |
| Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy ChildrenNCT05634811results2026-05-07Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 1Randomized · Quadruple-masked · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: VLA15 · Other: Normal Saline | Lyme Disease | 3,547 | 2025-07-21actual | — | 2026-05-07 |
| A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy MenNCT07015918Total recovery of radioactivity expressed as a percent of total oral radioactive dose administered.Open-label · Basic science | Phase 1 | Completed | Drug: [14C] PF-07976016, PF-07976016, [14C] PF-07976016 | Healthy Male Volunteers | 8 | 2025-07-16actual | — | 2025-09-10 |
| A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With CancerNCT06580938Number of Participants With Dose-Limiting Toxicity (DLT) (Parts 1 and 2)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns | Biological: PF-07921585, Sasanlimab | Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer | 4 | 2025-07-14actual | — | 2026-03-23 |
| A Study to Learn More About the Study Medicine PF-07275315 in Healthy Chinese Adult ParticipantsNCT06675188Maximum Observed Plasma Concentration (Cmax)Randomized · Quadruple-masked · Other | Phase 1 | Completed | Drug: PF-07275315 · Other: Placebo | Healthy | 13 | 2025-07-14actual | — | 2025-08-03 |
| Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®NCT03445637observationalTreatment-related adverse events during first 3 months | — | Completed | — | Breast Neoplasm | 552 | 2025-07-13actual | — | 2025-11-24 |
| A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post MenopauseNCT06465368results2026-07-15Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: PF-07220060, letrozole | Breast Cancer | 121 | 2025-07-10actual | — | 2026-07-15 |
| A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or OverweightNCT06712836Percent change from baseline in body weight at Week 28Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: MET097, Placebo | Obesity, Overweight or Obesity | 239 | 2025-07-03actual | — | 2026-05-29 |
| Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in JapanNCT05399329observationalReal-World Progression-Free Survival (rwPFS) of palbociclib plus ET as first line treatment for HR+/HER2- ABC | — | Completed | Drug: Palbociclib, Endocrine therapy | Breast Cancer | 693 | 2025-06-27actual | — | 2026-04-09 |
| A Study to Learn About the Study Medicine - Precedex in Children From Japan.NCT06085573observationalNumber of participants with adverse drug reactions (ADRs) | — | Completed | Drug: Dexmedetomidine Hydrochloride | Sedation | 111 | 2025-06-20actual | — | 2025-08-21 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults.NCT06920498Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: PF-07941944, Placebo, Midazolam | Healthy Participants | 25 | 2025-06-19actual | — | 2025-07-17 |
| HER2 and LA/mUC: A Multi-country Chart Review Cohort StudyNCT05902494observationalReal-world Objective Response Rate (rwORR) per modified response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) | — | Completed | — | Urothelial Carcinoma | 389 | 2025-06-18actual | — | 2025-07-20 |
| A Study to Learn About How Different Forms of Study Medicine PF-07248144 Are Taken Up Into the Blood in Healthy AdultsNCT07117799Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for PF-07248144 Form 1 uncoated tabletRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: PF-07248144, PF-07248144, PF-07248144 | Healthy Adults | 24 | 2025-06-18actual | — | 2025-12-01 |
| A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their InfantsNCT06325657results2026-07-02Percentage of Maternal Participants With Prespecified Local Reactions Within 7 Days After VaccinationRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: RSVpreF vaccine, Placebp | Respiratory Syncytial Virus | 681 | 2025-06-11actual | — | 2026-07-02 |
| A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy AdultsNCT06837259Maximum Observed Plasma Concentration (Cmax) of PF-07328948Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: PF-07328948, cyclosporine, clarithromycin | Healthy Adults | 26 | 2025-06-11actual | — | 2026-02-02 |
| A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in IndiaNCT06086353observationalNumber of Adverse events with Tafamidis | — | Completed | Drug: Tafamidis | Transthyretin Amyloid Cardiomyopathy | 6 | 2025-06-06actual | — | 2025-11-20 |
| Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 VaccineNCT06703190observationalNumber of Pfizer/BioNTech 2024-2025 formulation vaccinated patients who test positive for SARS-CoV-2 ≥14 days after receipt of vaccine | — | Terminatedsponsor's stated reason: This secondary data analysis of symptomatic CVS MinuteClinics patients testing for SARS-CoV-2 was terminated due to incomplete data on KP.2 vaccination status (exposure). Termination was not based on any safety concerns or regulatory requirements. | Biological: Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated, Not vaccinated with 2024-2025 formulated COVID-19 vaccine | COVID-19 | 1 | 2025-06-06actual | — | 2025-11-06 |
| A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.NCT05879718results2026-08-11Change From Baseline in Type 1 Interferon (IFN) Gene Signature (GS) Score in Lesional Skin at Week 12Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Pfizer has made an internal business decision to not continue this study. This decision was not due to safety concerns or clinical effect reasons or requests from any regulatory authorities. | Drug: Placebo, PF-06823859 | Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous | 8 | 2025-06-05actual | — | 2026-08-11 |
| A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid ArthritisNCT05891600observationalAdherence (Pharmacy claims source) | — | Terminatedsponsor's stated reason: The study was terminated following a comprehensive review of the collected data and an assessment of the study's completeness. This decision was made to maintain scientific standards and ethical conduct, and to prevent potentially inaccurate results | Drug: Etaneracept Smartclic | Rheumatoid Arthritis | 60 | 2025-05-30actual | — | 2025-11-20 |
| A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian AdultsNCT05989048results2026-05-22Percentage of Participants With Pain Freedom at 2 Hours Post-doseRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Zavegepant, Placebo | Migraine | 1,414 | 2025-05-30actual | — | 2026-05-22 |
| A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world SettingsNCT07200128observational% of patients for whom their clinician was "satisfied" with current control of alopecia areata | — | Completed | Drug: Ritlecitinib | Severe Alopecia Areata | 123 | 2025-05-30actual | — | 2026-06-10 |
| Secondary Databased Post-marketing Surveillance Study of BNT162b2NCT06743334observationalFrequency of Adverse Events of Special Interest (AESI) - Measure of Occurrence | — | Completed | Biological: Tozinameran (BNT162b2), Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1), Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5) | COVID-19, SARS-CoV-2 | 14,302,529 | 2025-05-28actual | — | 2026-07-10 |
| A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy AdultsNCT06911788Dose-normalized (dn) Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Vepdegestrant after oral administrationOpen-label · Other | Phase 1 | Completed | Drug: Vepdegestrant (Reference), Vepdegestrant (Test) | Healthy Participants | 10 | 2025-05-23actual | — | 2025-06-29 |
| A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsNCT05194072Number of participants with adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns | Drug: Felmetatug Vedotin, Pembrolizumab | Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma | 250 | 2025-05-14actual | — | 2026-01-09 |
| A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060NCT06897683Plasma PF-07220060 Maximum Observed Plasma Concentration (Cmax)Non-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: PF-07220060, Carbamazepine ER Tablet | Healthy Adults | 14 | 2025-05-11actual | — | 2025-11-25 |
| Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or ObesityNCT06910839Steady state area under the concentration-time profile for PF-07976016Open-label · Basic science | Phase 1 | Terminatedsponsor's stated reason: The sponsor has made the decision to discontinue development of danuglipron (PF-06882961). As such, this study was discontinued prior to PF-06882961 administration. | Drug: PF-07976016, PF-06882961 | Overweight, Obesity | 21 | 2025-05-01actual | — | 2025-08-07 |
| Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern CaliforniaNCT04848584observationalTest Negative Design Outcome: VE calculated as 1 minus the odds ratio (OR) comparing the odds of being vaccinated with 2 doses with BNT162b2 for hospitalized cases and controls, multiplied by 100%. | — | Completed | Biological: Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 BA.4/5 bivalent, XBB.1.5-adapted vaccinated | COVID-19 | 1 | 2025-04-30actual | — | 2025-07-29 |
| Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia BNCT03938792results2026-08-14Model-Based Annualized Bleeding Rate (ABR) of Treated Bleeding Events: Inhibitor Cohort (Participants With Prior OD Therapy at OP)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: PF-06741086 | Hemophilia A, Hemophilia B | 188 | 2025-04-29actual | — | 2026-08-14 |
| Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBCNCT04937660results2026-06-10observationalPercentage of Participants Who Were Progression Free at 6 Months Post Palbociclib InitiationStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | — | Metastatic Breast Cancer | 185 | 2025-04-29actual | — | 2026-06-10 |
| Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)NCT04155541results2026-06-11observationalThe Number and Percentage of Participants With Interstitial Lung Disease (ILD)Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: dacomitinib hydrate | EGFR Mutation-positive Inoperable or Reccrent NSCLC | 40 | 2025-04-25actual | — | 2026-06-11 |
| A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's DiseaseNCT04173273results2026-07-01Percentage of Participants With Endoscopic Response by Simple Endoscopic Score in Crohn's Disease (SES-CD) at Week 14: SSARandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: APD334_202_SAP_substudy 1_ph2B_CT 1_09AUG2023 ↗ · Statistical Analysis Plan: APD334-202_SAP_Substudy 1-Ph2B_CT 2_06OCT2024. ↗ · Statistical Analysis Plan: APD334_202_SAP_substudy A_24May2023 ↗ · Statistical Analysis Plan: APD334_202_SAP_substudy 3_16May2025 ↗ · Statistical Analysis Plan: APD334_202_SAP_substudy 4_03JUL2025 ↗ | Phase 2/3 | Terminatedsponsor's stated reason: The study was prematurely discontinued due to a lack of efficacy in sub-study 1 | Drug: Etrasimod, Etrasimod, Placebo | Crohn's Disease | 379 | 2025-04-23actual | — | 2026-07-01 |
| A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.NCT07090486observationalCardio-pulmonary Measurement A: Change in rate of cardiopulmonary-related healthcare utilization in patients that received nirmatrelvir-ritonavir compared to not received. | — | Completed | Drug: nirmatrelvir-ritonavir | COVID-19 | 14,000 | 2025-04-15actual | — | 2025-07-29 |
| Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous FungiNCT05630976results2026-05-27Number of Participants With Treatment Emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Isavuconazole | Invasive Fungal Disease | 70 | 2025-04-11actual | — | 2026-05-27 |
| A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes MellitusNCT06279234Number of Participants Reporting Adverse EventsRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Placebo, Rosuvastatin, Midazolam, Omeprazole, PF-06954522 | Type 2 Diabetes Mellitus (T2DM), Obesity | 50 | 2025-04-11actual | — | 2025-06-03 |
| A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy AdultsNCT06705569Area under the concentration-time curve (AUCinf)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Tafamidis 61 mg free acid tablet (Test), Tafamidis 61 mg free acid capsule (Reference) | Healthy | 22 | 2025-04-04actual | — | 2025-05-28 |
| Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive MedicationsNCT05518123results2026-05-22Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Rimegepant, Placebo | Migraine | 962 | 2025-03-31actual | — | 2026-05-22 |
| Vyndaqel Capsules Special Investigation (ATTR-CM)NCT04108091results2026-05-18observationalNumber of Participants With Adverse Drug ReactionsStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: Treatment for TTR amyloidosis, Treatment for TTR amyloidosis | Transthyretin (TTR) Amyloid Cardiomyopathy | 1,214 | 2025-03-27actual | — | 2026-05-18 |
| Safety and Efficacy of Trastuzumab BSNCT04181333results2026-04-14observationalThe Incidence of Adverse Drug Reactions (ADRs)Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: TRASTUZUMAB BS | Gastric Cancer | 8 | 2025-03-27actual | — | 2026-04-14 |
| A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19NCT05386472Apparent Oral Clearance (CL/F)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The trial prematurely terminated due to the inability to recruit the planned number of subjects. The decision to terminate the trial was not based on any safety concerns. | Drug: nirmatrelvir, ritonavir | COVID-19 | 25 | 2025-03-26actual | — | 2026-08-17 |
| A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or ObeseNCT06567327Steady-state area under the concentration-time profile from time zero to 24 hours (AUC24) for danuglipronNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Danuglipron, Atorvastatin, Rosuvastatin | Obesity | 82 | 2025-03-16actual | — | 2025-08-06 |
| RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database StudyNCT06790420results2026-05-15observationalIncidence of Infections Which Requires Procedures, Medication or HospitalizationStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: Rituximab Pfizer, Rituxan | Lymphoma | 2,703 | 2025-03-14actual | — | 2026-05-15 |
| A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.NCT06467370observationalSatisfaction with prescribed medication | — | Completed | — | Migraine | 467 | 2025-03-11actual | — | 2026-06-30 |
| Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan UseNCT05509400results2026-04-21Percentage of Participants With Pain Relief at 2 Hours Post-Dose: DBT PhaseRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Rimegepant, Placebo, Rimegepant | Migraine | 813 | 2025-03-10actual | — | 2026-04-21 |
| A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.NCT06541678AUCinf (if data permits otherwise AUClast): to estimate the effect of a single dose of cyclosporine on the single-dose PK of a MR formulation of danuglipron in healthy adult participants.Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Danuglipron, Cyclosporine, Itraconazole | Healthy | 16 | 2025-03-10actual | — | 2025-08-03 |
| A Study of Ponsegromab in People With Heart FailureNCT05492500results2026-03-18Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ)-23 - Clinical Summary Score (CSS) at Week 22: Cohort A, Ponsegromab 300 mg Versus PlaceboRandomized · Quadruple-masked · Supportive careStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Following a prespecified interim analysis, and in consultation with the independent Data Monitoring Committee, the Sponsor terminated the study | Drug: Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Open-label, PK Cohort (Cohort B): ponsegromab medium dose, Open-label, PK Cohort (Cohort B): ponsegromab high dose, Optional Cohort C: Ponsegromab low dose, Optional Cohort D: Ponsegromab high dose · Other: Main cohort (Cohort A): Matched placebo, Optional Cohort C: Matched placebo, Optional Cohort D: Matched placebo | Heart Failure | 455 | 2025-03-05actual | — | 2026-03-18 |
| A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care TherapiesNCT06592222observationalProgression-free survival | — | Completed | Drug: Elranatamab, Standard of care | Multiple Myeloma | 4 | 2025-03-03actual | — | 2025-05-20 |
| A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.NCT06085924observationalCohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Required Intensive Care Unit (ICU) | — | Completed | Drug: SoC · Other: Disease description | COVID-19 | 2,315,187 | 2025-02-28actual | — | 2026-06-22 |
| A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood in Healthy AdultsNCT06645938Maximum Observed Plasma Concentration (Cmax) of VepdegestrantRandomized · Open-label · Other | Phase 1 | Completed | Drug: single dose of vepdegestrant as tablet formulation (Treatment A), single dose of vepdegestrant as tablet formulation (Treatment B) | Healthy | 12 | 2025-02-20actual | — | 2025-05-25 |
| A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy AdultsNCT06706869Maximum Observed Plasma Concentration (Cmax)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: PF-07258669, Itraconazole | Healthy | 26 | 2025-02-20actual | — | 2025-08-03 |
| A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate CancerNCT05968599results2026-02-25observationalOverall Survival (OS): Adjusted Using Inverse Probability Treatment Weighting (IPTW)Study Protocol and Statistical Analysis Plan ↗ | — | Completed | Drug: Enzalutamide, Abiraterone acetate | Prostatic Neoplasms, Castration-Resistant | 2,731 | 2025-02-14actual | — | 2026-02-25 |
| MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple MyelomaNCT05090566results2026-02-23SSA: Number of Participants With Dose Limiting Toxicities (DLTs)- Phase 1b Dose EscalationNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2 expansion of this study. The reason for study termination is not due to any safety concerns or requests from regulatory authorities. | Drug: Elranatamab + Nirogacestat, Elranatamab + lenalidomide + dexamethasone | Multiple Myeloma | 46 | 2025-02-13actual | — | 2026-04-24 |
| GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)NCT05632354results2026-03-19Number of Participants With Treatment Emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: Study terminated as data obtained from this non-placebo-controlled trial may not be informative for the interpretation of the benefits and risks of osivelotor | Drug: Osivelotor | Sickle Cell Disease | 47 | 2025-02-13actual | — | 2026-03-19 |
| A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.NCT06586216Maximum Observed Plasma Concentration (Cmax) of PF-07817883Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: PF-07817883 | COVID-19 | 16 | 2025-02-13actual | — | 2025-02-19 |
| Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic ArthritisNCT01500551results2026-03-23Number of Participants With Laboratory Test AbnormalitiesOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: Tofacitinib, Tofacitinib | Juvenile Idiopathic Arthritis | 302 | 2025-02-12actual | — | 2026-03-23 |
| A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese MarketNCT07096024observationalThe hazard ratios of ILD in palbociclib plus fulvestrant to new users of fulvestrant alone | — | Completed | Drug: palbociclib plus fulvestrant, fulvestrant | Breast Neoplasms | 95,637 | 2025-02-07actual | — | 2026-07-10 |
| A Study About Modified RNA Vaccines Against Influenza in Healthy AdultsNCT06436703results2026-06-12SSA: Percentage of Participants With Local Reactions for up to 7 Days Following VaccinationRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: Influenza ModRNA Vaccine, Quadrivalent Influenza Vaccine (QIV) | Influenza, Human | 1,202 | 2025-02-05actual | — | 2026-06-12 |
| A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in KoreaNCT06593587results2026-02-09Percentage of Participants With Local Reactions Within 7 Days After VaccinationRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: RSVpreF Vaccine · Other: Placebo | Respiratory Syncytial Virus | 378 | 2025-02-03actual | — | 2026-02-09 |
| A Study to Learn If the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine Ibuzatrelvir in Healthy AdultsNCT06646042Maximum Observed Plasma Concentration (Cmax) of ibuzatrelvirRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: ibuzatrelvir, carbamazepine ER | Healthy | 12 | 2025-01-17actual | — | 2025-02-03 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 Are Tolerated and Act in the Body in Healthy Adults.NCT06532383Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)Randomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: PF-07940369, Placebo | Healthy | 22 | 2025-01-16actual | — | 2025-08-28 |
| A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy AdultsNCT06693518CmaxRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Treatment B, Treatment A | SARS-CoV-2 Infections | 20 | 2025-01-15actual | — | 2025-01-24 |
| A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsNCT06285097Number of patients with dose limiting toxicities (DLTs) in dose escalation (Part 1A and Part 1B)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns. | Drug: PF-07820435 · Biological: Sasanlimab | Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma | 9 | 2025-01-03actual | — | 2025-09-17 |
| This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or ObesityNCT06857617(Part C) Percent change from baseline in body weight at Week 12 (Day 85).Randomized · Double-masked · Treatment | Phase 1/2 | Completed | Biological: (Part C) MET097, (Part C) Placebo | Obesity and Overweight | 120 | 2025-01-03actual | — | 2026-01-28 |
| Besponsa Post Marketing Surveillance StudyNCT04307134results2025-12-31observationalNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: Inotuzumab ozogamicin | Hematologic Malignancy | 108 | 2024-12-24actual | — | 2025-12-31 |
| A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy AdultsNCT06670170Area Under the Curve - infinity - AUCinf (as data permit, otherwise AUClast).Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: PF-07976016 Formulation A, PF-07976016 Formulation B | Healthy Volunteers | 12 | 2024-12-24actual | — | 2025-09-22 |
| A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)NCT06072196results2025-12-31observationalDuration of NHT TreatmentStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Drug: Novel hormonal therapy | Prostatic Neoplasms | 3,017 | 2024-12-18actual | — | 2025-12-31 |
| A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or ObesityNCT06568731Steady-state area under the concentration-time profile from time zero to 24 hours (AUC24) for danuglipronOpen-label · Basic science | Phase 1 | Completed | Drug: Danuglipron | Obesity | 23 | 2024-12-18actual | — | 2025-01-20 |
| A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)NCT03587116results2025-11-06Annualized Bleeding Rate (ABR) for Treated Bleeds and All Bleeds During Prospective Data Collection Period in Hemophilia B Participants: Efficacy Analysis SetOpen-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Standard of Care FIX Replacement therapy, Standard of Care FVIII Replacement therapy | Hemophilia B, Hemophilia A | 212 | 2024-12-13actual | — | 2025-11-06 |
| Description of Relugolix Use in Patients With Prostate Cancer Within the VHANCT06462014results2025-12-11observationalNumber of Participants According to Geographic RegionStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Drug: Relugolix | Prostate Cancer | 507 | 2024-12-13actual | — | 2025-12-11 |
| Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.NCT04152018Number of participants with Dose-limiting toxicities (DLT) for Dose Escalation and Dose FindingNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority. | Drug: PF-06940434, PF-06801591 | Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer | 85 | 2024-12-10actual | — | 2025-05-28 |
| A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult ParticipantsNCT06177457Part A:Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)Randomized · Double-masked · Basic science | Phase 1 | Completed | Drug: PF-07293893, Placebo, Midazolam | Healthy Participants | 88 | 2024-12-02actual | — | 2024-12-18 |
| Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)NCT03885037results2026-01-06observationalNumber of Participants With Adverse Drug Reactions (ADRs)Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: Infliximab [infliximab biosimilar 3] | Rheumatoid Arthritis | 77 | 2024-11-29actual | — | 2026-01-06 |
| Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness SurveyNCT06680206results2026-01-22observationalNumber of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC])Study Protocol and Statistical Analysis Plan ↗ | — | Completed | Drug: Rimegepant, Triptans | Migraine | 1,395 | 2024-11-20actual | — | 2026-01-22 |
| Study of PF-07265807 in Participants With Metastatic Solid Tumors.NCT04458259Parts 1, 2, and 3: Number of participants with dose limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities. | Drug: PF-07265807, Sasanlimab, Axitinib | Neoplasm Metastasis | 88 | 2024-11-15actual | — | 2026-06-04 |
| A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming SevereNCT07072793results2026-01-12observationalNumber of Participants According to Age Group: Unmatched ParticipantsStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Drug: nirmatrelvir-ritonavir | COVID-19 (Coronavirus Disease 2019) | 131,005 | 2024-11-15actual | — | 2026-02-09 |
| Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031NCT03573882results2025-11-18Number of Participants With Sickle Cell Disease (SCD)-Related Treatment Emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Emerging clinical data evaluated by Pfizer and shared with regulatory authorities indicates that the risk profile of voxelotor in people with SCD exceeds the benefits observed in previously generated global research and requires further assessment. | Drug: Voxelotor | Sickle Cell Disease | 179 | 2024-11-12actual | — | 2025-11-18 |
| A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.NCT06392230Total recovery of radioactivity in urine, feces, and total excreta (urine + feces) as percentage of total radioactive dose administeredOpen-label · Basic science | Phase 1 | Completed | Drug: Oral [14C] PF-06821497, Oral PF-06821497, IV [14C] PF-06821497 | Healthy Participants | 6 | 2024-11-11actual | — | 2025-01-23 |
| A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in ChinaNCT05896774Number of Participants With Dose-Limiting Toxicity (DLT)Open-label · Treatment | Phase 1 | Completed | Drug: Maplirpacept | Non-Hodgkin Lymphoma, Multiple Myeloma | 10 | 2024-11-06actual | — | 2024-11-20 |
| Open-Label Extension of VoxelotorNCT04188509results2025-11-13Number of Participants With Treatment Emergent Adverse Events (AEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Emerging clinical data evaluated by Pfizer and shared with regulatory authorities indicates that the risk profile of voxelotor in people with SCD exceeds the benefits observed in previously generated global research and requires further assessment. | Drug: Voxelotor | Sickle Cell Disease | 162 | 2024-11-01actual | — | 2025-11-13 |
| Monitoring Activity And Gait In ChildrenNCT04823650results2025-12-11observationalCohort A: Gait Speed Measured by APDM, GAITRite Walkway and ActiGraph Devices for Walk at Natural, Slow and Fast Speed TasksStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Device: COHORT A: Actigraph, Panoramic Bracelet and GENEActiv | Child, Preschool, Child, Adolescent | 87 | 2024-10-28actual | — | 2025-12-11 |
| Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing RegimensNCT05217927results2025-12-16Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, Placebo comparator dosing | Migraine | 1,415 | 2024-10-22actual | — | 2025-12-16 |
| To Learn How Different Forms of Study Medicine Are Taken up Into the Blood and the Effect of Food on Study Medicine in Healthy AdultsNCT06593054Maximum Observed Plasma Concentration [Cmax] of cis-CTB and AVI following test formulation administration in fasted or fed stateRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Ceftibuten, Avibactam prodrug, CTB-AVP in Tablet | Healthy | 13 | 2024-10-11actual | — | 2025-05-21 |
| Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCDNCT04930445results2025-12-31observationalChange in Hemoglobin From Pre-Oxbryta Treatment (Baseline) Through Month 60 Post-OxbrytaStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Terminatedsponsor's stated reason: Emerging clinical data evaluated by Pfizer and shared with regulatory authorities indicates that the risk profile of voxelotor in people with SCD exceeds the benefits observed in previously generated global research, and requires further assessment. | Drug: Oxbryta® (voxelotor) 500mg Tablets | Sickle Cell Disease | 265 | 2024-10-10actual | — | 2025-12-31 |
| A Study to Learn How Different Forms of The Study Medicine Called Phenytoin Are Taken up Into the Blood in Healthy AdultsNCT06466473Area Under the Plasma Concentration-time Profile From Time Zero to the Time of Last Quantifiable Concentration (AUClast)Randomized · Open-label · Health services research | Phase 1 | Completed | Drug: Phenytoin (Ascoli), Phenytoin (Vega Baja) | Healthy | 35 | 2024-10-04actual | — | 2024-10-08 |
| A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic MalignanciesNCT05567887Number of Participants with Dose Limiting Toxicity (DLT) in lymphomaOpen-label · Treatment | Phase 1 | Completed | Drug: maplirpacept (PF-07901801) | Lymphoma, Multiple Myeloma | 7 | 2024-10-02actual | — | 2024-11-06 |
| A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in FranceNCT05838664results2025-12-24observationalIncidence Rate (Per 1000 Participant-years) of Stroke in Non-valvular Atrial Fibrillation (AF) Participants Exposed to Oral Anticoagulation (OAC) and Unexposed to OACStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: No OAC, VKA, apixaban, rivaroxaban, dabigatran | Atrial Fibrillation | 2,140,403 | 2024-09-30actual | — | 2025-12-24 |
| A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) InfectionNCT06079320results2025-11-10Number of Participants With Respiratory Syncytial Virus (RSV) Related Hospitalization or Death From Any Cause Through Day 28Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study. | Drug: Sisunatovir, Placebo | Respiratory Syncytial Virus Infection | 16 | 2024-09-30actual | — | 2025-11-10 |
| Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy AdultsNCT06153758Parts A, C and D only: Area under the concentration-time curve from time zero extrapolated to infinite time (AUCinf), as data permit, for danuglipron in the fasted stateNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Danuglipron | Healthy Participants, Healthy Subjects | 33 | 2024-09-30actual | — | 2024-10-21 |
| A Study to Learn How the Study Medicine Called Zavegepant is Taken Up Into Blood and Breast Milk of Healthy Breast-Feeding WomenNCT06453356Area Under the Breast Milk Concentration-time Profile from time 0 extrapolated to infinite time (AUCinf), if data permitOpen-label · Treatment | Phase 1 | Completed | Drug: Zavegepant 10mg | Healthy | 12 | 2024-09-26actual | — | 2024-10-08 |
| A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.NCT06473519results2025-09-25Geometric Mean Titer (GMT) of Serum Neutralizing Titers (NTs) for Respiratory Syncytial Virus Subgroup A (RSV A) and Respiratory Syncytial Virus Subgroup B (RSV B) Before VaccinationRandomized · Open-label · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: RSVpreF MDV, RSVpreF SDV | Respiratory Syncytial Virus (RSV) | 453 | 2024-09-20actual | — | 2025-09-25 |
| A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver FunctionNCT06340347Area under the whole blood and plasma concentration versus time curve (AUC) from time zero (pre-dose) to the last quantifiable concentration (AUClast) of osivelotorNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Osivelotor | Liver Diseases | 8 | 2024-09-18actual | — | 2025-01-10 |
| A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy AdultsNCT06237049results2025-09-30Percentage of Participants Who Reported Any Local Reaction up to 7 Days Following VaccinationRandomized · Single-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), RIV · Other: Normal saline placebo | Influenza, Human, SARS-CoV-2 Infection, COVID-19 | 644 | 2024-09-13actual | — | 2025-09-30 |
| BESPONSA Injection 1 mg Special InvestigationNCT05923112results2025-12-05observationalThe Incidence of Adverse Drug ReactionsStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | — | Acute Lymphocytic Leukemia | 421 | 2024-09-06actual | — | 2025-12-05 |
| A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSVNCT06102174results2025-12-30Number of Participants With Treatment Emergent Adverse Events (TEAEs)Randomized · Triple-masked · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study | Drug: Placebo, Active | Respiratory Syncytial Virus Infections | 10 | 2024-09-03actual | — | 2025-12-30 |
| A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy AdultsNCT06393517Area Under the Curve from time zero to extrapolated infinite time (AUCinf) of PF-06954522 to evaluate the relative bioavailability of three PF-06954522 formulations administered in the fasted state.Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: PF-06954522 IR (Formulation 1), PF-06954522 MR (Formulation 2), PF-06954522 MR (Formulation 3) | Healthy Participants | 23 | 2024-09-01actual | — | 2024-10-08 |
| A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and CancerNCT05643885results2025-10-20observationalMean All-Cause Healthcare Costs Per Participant Per Month (PPPM) for VTE EventsStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | — | Thromboembolism | 7,304 | 2024-08-30actual | — | 2025-10-20 |
| A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)NCT05709158observationalNumber of Participants With Risk Factors for Grade 4 Neutropenia in Users of Palbociclib | — | Completed | — | Breast Cancer | 4,184 | 2024-08-30actual | — | 2026-06-02 |
| A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)NCT05912933observationalNumber of Participants With/Without Hepatic Impairment for Grade 4 Neutropenia in New Users of Palbociclib | — | Completed | — | Breast Cancer | 1,342 | 2024-08-30actual | — | 2026-06-30 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy AdultsNCT06106009Part A: Number of Participants With Treatment Emergent Adverse Events Following Single DosesRandomized · Double-masked · Other | Phase 1 | Completed | Drug: PF-07976016, Placebo, Midazolam | Healthy | 117 | 2024-08-19actual | — | 2024-09-23 |
| A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIVNCT05794191results2025-10-20observationalPCV13 Vaccine Effectiveness (VE) for First Event of Invasive Pneumococcal Disease (IPD): Overall Follow-upStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Biological: Vaccine Administration | HIV, Pneumonia, Infections, Pneumococcal | 350,399 | 2024-08-15actual | — | 2025-10-20 |
| A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In CombinationNCT06448364PART 1: Number of participants with Dose-limiting toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic business decision | Biological: PF-07329640, sasanlimab, bevacizumab | Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Cancer, Melanoma | 4 | 2024-08-15actual | — | 2024-11-06 |
| A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver DysfunctionNCT05224609Single dose Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (inf)] of lorlatinibNon-randomized · Open-label · Other | Phase 1 | Completed | Drug: Lorlatinib | Moderate Hepatic Impairment, Severe Hepatic Impairment, Healthy Volunteers | 21 | 2024-08-13actual | — | 2024-08-30 |
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell LymphomaNCT05626322results2025-09-05Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: The trial terminated due to the inability to recruit the planned number of subjects. The decision was not based on any safety and/or efficacy concerns | Drug: Maplirpacept, Tafasitamab, Lenalidomide | Diffuse Large B-Cell Lymphoma | 6 | 2024-08-12actual | — | 2025-09-05 |
| A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaNCT05687032results2025-08-07Percentage of Participants With Complete Remission (CR) or Complete Remission With Incomplete Hematological Recovery (CRi) as Per Investigator's Assessment According to a Modified Cheson CriteriaOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: inotuzumab ozogamicin | Acute Lymphoblastic Leukemia | 44 | 2024-08-07actual | — | 2025-12-03 |
| A STUDY TO LEARN HOW THE STUDY MEDICINE CALLED PF-07293893 AFFECTS MUSCLE BIOMARKERS OF HEALTHY ADULTSNCT06413693Change from baseline of skeletal muscle pACC/tACC ratioRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: PF-07293893, Placebo | Healthy Participants | 31 | 2024-08-05actual | — | 2024-11-20 |
| Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims DataNCT06199934results2025-09-10observationalNumber of Participants COVID-19 DiagnosisStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Biological: Vaccination | SARS-CoV-2, COVID-19 Vaccines | 19,853,610 | 2024-07-31actual | — | 2025-09-10 |
| A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without FoodNCT06369454Site of capsule disintegration and MR microsphere dispersionRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Ritlecitinib | Healthy Volunteers | 12 | 2024-07-31actual | — | 2024-08-28 |
| A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in AustraliaNCT06624020observationalDemographic characteristic of participants (CDK4/6i cohort): year of birth | — | Completed | — | Breast Neoplasms | 1,128 | 2024-07-31actual | — | 2026-06-02 |
| Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical PracticeNCT04517669results2025-10-14observationalPercentage of Participants Who Achieved Low Disease Activity (LDA) Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | — | Psoriatic Arthritis | 116 | 2024-07-30actual | — | 2025-10-14 |
| Study of GBT021601 in Participants With Renal ImpairmentNCT05878704Concentration of GBT021601 in whole blood and plasmaOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business decision to terminate the trial after the completion of Part 1: Cohort 1 (severe renal impairment). The decision to terminate the trial was not due to any potential safety concerns. | Drug: GBT021601 | Renal Impairment | 8 | 2024-07-29actual | — | 2024-10-15 |
| Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 YearsNCT06130410results2025-07-14observationalProportion of Participants With Adverse Reaction (AR)Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Biological: COMIRNATY intramuscular injection | SARS-CoV-2, COVID-19 | 25 | 2024-07-26actual | — | 2025-07-14 |
| A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic DermatitisNCT05250115results2025-09-29observationalPercentage of Participants Who Achieved Investigator's Global Assessment (IGA) Score of Clear (0) or Almost Clear (1) at Month 3Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Terminatedsponsor's stated reason: Business decision: Due to the slow recruitment, the sponsor decided to discontinue the study early. | — | Dermatitis, Atopic | 112 | 2024-07-25actual | — | 2025-09-29 |
| A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy AdultsNCT06347861Maximum observed concentration (Cmax) for vepdegestrantRandomized · Open-label · Other | Phase 1 | Completed | Drug: single dose of vepdegestrant as tablet formulation (Treatment A), single dose of vepdegestrant as tablet formulation (Treatment B), single dose of vepdegestrant as tablet formulation (Treatment C) | Healthy | 52 | 2024-07-22actual | — | 2024-10-01 |
| A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults.NCT06105983Maximum Observed Plasma Concentration (Cmax)Randomized · Open-label · Other | Phase 1 | Completed | Drug: Sisunatovir, Rabeprazole 40 mg, Sisunatovir suspension, Rabeprazole 20 mg | Healthy | 40 | 2024-07-19actual | — | 2025-04-24 |
| A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid ArthritisNCT06418529results2025-07-31observationalIncidence Rate of Low Disease Activity (LDA) or Remission Based on Clinical Disease Activity Index (CDAI) at 6-Months Follow-up: Tofacitinib vs. TNFiStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Drug: tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept, tocilizumab or sarilumab | Rheumatoid Arthritis | 21,340 | 2024-07-19actual | — | 2025-07-31 |
| A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple MyelomaNCT03530683Phase 1a: Number of adverse events (AE) by severityNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: A business decision was made by Pfizer to terminate the study. Termination was not due to any safety concerns, requests from regulatory authorities, changes to the benefit/risk profile or any new concerns regarding the investigational product. | Drug: Maplirpacept (PF-07901801), Azacitidine, Venetoclax, Carfilzomib, Dexamethasone, Anti-CD20 Targeting agent, Isatuximab | Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma | 189 | 2024-07-18actual | — | 2024-09-03 |
| A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia ANCT03061201results2025-09-30Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: SB-525 (PF-07055480) | Hemophilia A | 13 | 2024-07-16actual | — | 2025-09-30 |
| A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast CancerNCT04539938results2025-07-31Confirmed Objective Response Rate (cORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 According to Investigator (INV) AssessmentOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: tucatinib, trastuzumab deruxtecan | HER2 Positive Breast Cancer | 70 | 2024-07-15actual | — | 2026-03-23 |
| Real-World Study of Ceftazidime Avibactam in ChinaNCT05487586results2025-09-04observationalClinical Success Rate at Day 7Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Terminatedsponsor's stated reason: The study was prematurely discontinued due to slow enrollment and strategic considerations. This decision was not based on any safety or efficacy concerns. | Drug: ceftazidime avibactam group | Hospital Acquired Pneumonia, Ventilator Acquired Pneumonia, Complicated Intra Abdominal Infections | 220 | 2024-07-11actual | — | 2025-09-04 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy AdultsNCT05807490Part A: Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: PF-07328948, Placebo, PF-07328948, Placebo, PF-07328948, Placebo, PF-07328948, Placebo, PF-07328948, Placebo, PF-07328948, Placebo, PF-07328948, Placebo, PF-07328948, Placebo, PF-07328948, PF-07328948, Placebo, PF-07328948, Placebo, PF-07328948 | Healthy | 86 | 2024-07-10actual | — | 2024-07-19 |
| A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney FunctionNCT06037031Maximum Observed Plasma Concentration (Cmax)Non-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Drug: PF-07923568 | Renal Impairment | 16 | 2024-07-03actual | — | 2024-07-19 |
| Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine PreventionNCT05207865results2025-09-03Number of Participants With On-Treatment Adverse Events (AEs) (Frequency >=5%) According to IntensityOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Rimegepant | Migraine, Episodic Migraine, Phonophobia, Photophobia | 441 | 2024-07-02actual | — | 2025-09-03 |
| A Study to Learn About the Study Medicine Called PF-07054894 in People of Japanese OriginNCT06327880Number of participants with adverse events (AE) or serious adverse events (SAE)Randomized · Triple-masked · Other | Phase 1 | Completed | Drug: PF-07054894 or placebo | Healthy | 6 | 2024-07-02actual | — | 2024-08-05 |
| A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in MoroccoNCT05997485observationalDemographical Characteristics of Participants | — | Withdrawnsponsor's stated reason: The study was prematurely discontinued due to the substantial delay in initiation the study. This decision was not due to major safety concerns or requests from any regulatory authorities. | Drug: Nirmatrelvir/Ritonavir | COVID-19 Drug Treatment | 0 | 2024-06-30 | — | 2024-03-28 |
| A Study to Learn About How Loss of Liver Function Affects the Blood Levels of the Study Medicine Called PF-07817883.NCT05884554Maximum Observed Plasma Concentration (Cmax) of PF-07817883Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: PF-07817883 | COVID-19 | 21 | 2024-06-27actual | — | 2024-09-19 |
| Resolution of Sickle Cell Leg Ulcers With VoxelotorNCT05561140results2025-07-09Percentage of Participants Who Achieved Resolution of the Target Ulcers by Week 12 in Randomized Treatment PeriodRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Emerging clinical data evaluated by Pfizer and shared with regulatory authorities indicates that the risk profile of voxelotor in people with SCD exceeds the benefits observed in previously generated global research and requires further assessment. | Drug: Voxelotor Oral Tablet · Other: Placebo | Sickle Cell Disease, Leg Ulcers | 88 | 2024-06-26actual | — | 2025-07-09 |
| A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to AdultsNCT05831124Percentage of participants reporting local reactions within 7 days after vaccinationRandomized · Quadruple-masked · Prevention | Phase 1 | Completed | Other: Low dose multivalent pneumococcal conjugate vaccine formulation A, Low dose multivalent pneumococcal conjugate vaccine formulation B · Biological: Low dose of multivalent pneumococcal conjugate vaccine control, Standard dose multivalent pneumococcal conjugate vaccine control | Pneumococcal Disease | 90 | 2024-06-26actual | — | 2024-07-29 |
| Long-Term PF-06651600 for the Treatment of Alopecia AreataNCT04006457results2025-08-14Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up VisitNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Main study ↗ · Statistical Analysis Plan: sub study SAP ↗ | Phase 3 | Completed | Drug: PF-06651600 · Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine | Alopecia Areata | 1,057 | 2024-06-25actual | — | 2026-04-09 |
| A Study to Learn About Sickle Cell Disease In Adult PatientsNCT05407805results2026-06-10observationalPhysician-reported Medical Utilization (MU) Vaso-occlusive Crisis (VOC) RateStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Other: Electronic Diary | Sickle Cell Disease | 98 | 2024-06-24actual | — | 2026-06-10 |
| A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy AdultsNCT05923411Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time(AUCinf) of PF-07220060 to estimate relative bioavailability of PF-07220060 two tablet formulationsRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Single dose of PF-07220060 as first Tablet Formulation, Single dose of PF-07220060 as second Tablet Formulation, Single dose of PF-07220060 as first Tablet Formulation, Single dose of PF-07220060 as second Tablet Formulation, Single dose of PF-07220060 as a Tablet Formulation, Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration, Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration, Single dose of PF-07220060 as third tablet formulation | Healthy Participants | 113 | 2024-06-23actual | — | 2026-06-04 |
| Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative ColitisNCT04607837results2025-07-15Percentage of Participants Achieving Clinical Remission (CR) at Week 52 Using Modified Mayo Score (MMS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Etrasimod, Placebo | Ulcerative Colitis | 234 | 2024-06-19actual | — | 2025-07-15 |
| PF-07284892 in Participants With Advanced Solid TumorsNCT04800822Part 1 and Part 2- Number of participants with dose limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study was prematurely discontinued due to strategic reasons. The PF-07284892 program will continue | Drug: PF-07284892, lorlatinib, binimetinib, encorafenib · Biological: cetuximab | Solid Tumor | 53 | 2024-06-19actual | — | 2026-06-04 |
| A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.NCT06532357results2025-08-11observationalNumber of Participants Classified as Per Responses for Satisfaction of Pain IntensityStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | — | Migraine | 1,536 | 2024-06-10actual | — | 2025-08-22 |
| A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive CrisesNCT04935879results2025-12-02Rate of Vaso-occlusive Crises (VOCs) [Adjudicated] Through Week 48Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Inclacumab, Placebo | Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis | 241 | 2024-06-06actual | — | 2025-12-02 |
| A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and USNCT06504524results2025-06-27observationalOverall Survival (OS): C1071003 Cohort A Versus TM-MM Database Using Inverse Probability of Treatment Weights (IPTW) AnalysisStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Drug: Elranatamab, Standard of Care | Multiple Myeloma | 633 | 2024-05-31actual | — | 2025-06-27 |
| Study of Lorlatinib In People With ALK-positive Non-small Cell Lung CancerNCT04362072results2025-06-11Percentage of Participants With Confirmed Overall Objective Response (OR) as Per Independent Central Review (ICR) as Assessed by RECIST v1.1Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Lorlatinib | Carcinoma, Non-Small-Cell Lung | 71 | 2024-05-29actual | — | 2025-06-11 |
| Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart ReviewNCT04609319results2025-05-31observationalBody Mass Index (BMI): All Asian ParticipantsStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: Dacomitinib | Lung Cancer | 307 | 2024-05-28actual | — | 2025-05-31 |
| A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy ToddlersNCT06116591results2025-05-08Percentage of Participants With Local Reactions Within 7 Days After Dose 1Randomized · Open-label · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: mPnC candidate, mPnC control | Healthy Participants | 105 | 2024-05-27actual | — | 2025-05-08 |
| A Study to Learn How Different Forms of Study Medicine Tafamidis Are Taken Up Into The Blood in Healthy AdultsNCT06273839Area under the concentration-time curve (AUCinf)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Tafamidis 61 mg free acid tablet (Test 1), Tafamidis 70 mg free acid tablet (Test 1), Tafamidis 61 mg free acid capsule (Reference) | Healthy | 12 | 2024-05-27actual | — | 2024-06-26 |
| A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.NCT06291831results2025-08-19observationalNumber of Participants Classified Based on EducationStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: nirmatrelvir, ritonavir · Other: Controls | COVID-19 | 3,011 | 2024-05-14actual | — | 2025-08-19 |
| A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy PeopleNCT05411588Number of participants with Adverse Events (AEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: PF-07275315, Placebo | Healthy Volunteers | 65 | 2024-05-13actual | — | 2025-05-25 |
| A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 ExpressionNCT04569032results2025-05-15Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) by Revised Response Criteria for Malignant Lymphoma Criteria (Cheson 2007) by Central CD30 AssessmentNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: brentuximab vedotin, cyclophosphamide, doxorubicin, prednisone | Peripheral T-cell Lymphoma | 82 | 2024-05-09actual | — | 2026-08-13 |
| A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy AdultsNCT06190561Area under the whole blood concentration versus time curve (AUC) from time zero (pre-dose) to 336 hours (AUC336) of PF-07940367 dose to evaluate pharmacokinetic comparability of two PF-07940367 productsRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: PF-07940367, PF-07940367 | Healthy | 40 | 2024-05-07actual | — | 2024-06-13 |
| A Preliminary Study to Evaluate PF-07264660 in Healthy ParticipantsNCT05496738Number of participants with treatment emergent treatment related adverse events (AE's)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: PF-07264660 intravenous single ascending dose, PF-07264660 subcutaneous multiple ascending dose · Other: Intravenous placebo, subcutaneous placebo | Healthy | 59 | 2024-05-06actual | — | 2024-06-06 |
| A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine VepdegestrantNCT06275841Maximum observed plasma concentration (Cmax) of vepdegestrant when vepdegestrant is administered aloneOpen-label · Other | Phase 1 | Completed | Drug: vepdegestrant, esomeprazole | Healthy | 12 | 2024-05-03actual | — | 2024-06-03 |
| Generate Real World Data On Tofacitinib Induction Therapy and Changes In Clinical and Patient Reported Outcomes.NCT05069259results2025-04-18observationalPercentage of Participants Who Achieved Clinical Response at Week 8Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Terminatedsponsor's stated reason: Study was terminated due to difficulty in enrolling targeted number of participants. There were no safety and/or efficacy concerns in the decision to stop enrollment. | Other: Stool sample collection | Ulcerative Colitis | 18 | 2024-04-30actual | — | 2025-12-19 |
| A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by InjectionNCT05732454results2025-05-08Part 1, DB Period: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: Per the results of the planned interim analysis, the study met futility criteria for efficacy so the trial was terminated. This decision was made for efficacy reasons only and is not due to any safety concerns. | Drug: etrasimod, Placebo | Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic | 58 | 2024-04-29actual | — | 2025-05-08 |
| A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMANCT04822350results2026-04-02observationalOverall Survival (OS): OverallStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: Avelumab | Urothelial Carcinoma | 596 | 2024-04-25actual | — | 2026-04-02 |
| A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed ForcesNCT06151418results2025-06-04observationalDuration of Therapy (DOT)Study Protocol and Statistical Analysis Plan ↗ | — | Completed | Drug: Novel hormonal therapy | Prostatic Neoplasms | 2,313 | 2024-04-23actual | — | 2025-06-04 |
| A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.NCT06307457results2025-06-29observationalProgression-Free Survival (PFS)Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: Palbociclib in combination with AI | Breast Cancer | 604 | 2024-04-19actual | — | 2025-06-29 |
| A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called MidazolamNCT06256510Maximum Observed Plasma Concentration (Cmax) of Midazolam when administered aloneOpen-label · Other | Phase 1 | Completed | Drug: Midazolam, Vepdegestrant | Healthy Participants | 15 | 2024-04-16actual | — | 2025-01-21 |
| A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy AdultsNCT06267963results2026-03-10Percentage of Total Radiocarbon (14C) Excreted in UrineRandomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Oral [14C]PF-07220060, Oral PF-07220060, IV [14C] PF-07220060 | Healthy Participants | 12 | 2024-04-12actual | — | 2026-03-10 |
| Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in FinlandNCT05701007results2026-01-29observationalBody Mass Index (BMI)Study Protocol and Statistical Analysis Plan ↗ | — | Completed | Drug: abiraterone, enzalutamide, docetaxel, apalutamide, cabazitaxel, Radium-223, Lutetium-177, degarelix, goserelin, leuprorelin, triptorelin | Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC) | 1,083 | 2024-04-10actual | — | 2026-01-29 |
| A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi ArabiaNCT06016556results2025-04-29observationalNumber of Participants Classified According to Education Level at Index DateStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: nirmatrelvir, ritonavir | Covid-19 | 250 | 2024-04-09actual | — | 2025-06-05 |
| A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.NCT05873751results2025-04-17observationalNumber of Participants With Gonococcal Infection After at Least 1 Dose of Trumenba to Determine Vaccine Effectiveness (VE)Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Biological: Trumenba Vaccine, MenACWY Vaccine | Gonorrhea, Chlamydia, Meningococcal Vaccines | 1,307,378 | 2024-03-31actual | — | 2025-04-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19